

Cellular interplay between cardiomyocytes and non-myocytes in diabetic cardiomyopathy

Ren Jie Phang^{1,2}, Rebecca H. Ritchie ^{3,4,5}, Derek J. Hausenloy^{6,7,8,9,10},
Jarmon G. Lees ^{1,11*}†, and Shiang Y. Lim ^{1,2,4,6†}

¹O'Brien Institute Department, St Vincent's Institute of Medical Research, 9 Princes Street, Fitzroy, VIC 3065, Australia; ²Department of Surgery, University of Melbourne, Parkville, VIC 3010, Australia; ³School of Biosciences, University of Melbourne, Parkville, VIC 3010, Australia; ⁴Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Parkville, VIC 3052, Australia; ⁵Department of Pharmacology, Monash University, Clayton, VIC 3800, Australia; ⁶National Heart Research Institute Singapore, National Heart Centre Singapore, Singapore, Singapore; ⁷Cardiovascular and Metabolic Disorders Programme, Duke-NUS Medical School, Singapore, Singapore; ⁸Yong Loo Lin School of Medicine, National University Singapore, Singapore, Singapore; ⁹The Hatter Cardiovascular Institute, University College London, London, UK; ¹⁰Cardiovascular Research Center, College of Medical and Health Sciences, Asia University, Taichung City, Taiwan; and ¹¹Department of Medicine, University of Melbourne, Parkville, VIC 3010, Australia

Received 1 December 2021; revised 16 February 2022; accepted 5 March 2022; online publish-ahead-of-print 7 April 2022

Abstract

Patients with Type 2 diabetes mellitus (T2DM) frequently exhibit a distinctive cardiac phenotype known as diabetic cardiomyopathy. Cardiac complications associated with T2DM include cardiac inflammation, hypertrophy, fibrosis, and diastolic dysfunction in the early stages of the disease, which can progress to systolic dysfunction and heart failure. Effective therapeutic options for diabetic cardiomyopathy are limited and often have conflicting results. The lack of effective treatments for diabetic cardiomyopathy is due in part, to our poor understanding of the disease development and progression, as well as a lack of robust and valid preclinical human models that can accurately recapitulate the pathophysiology of the human heart. In addition to cardiomyocytes, the heart contains a heterogeneous population of non-myocytes including fibroblasts, vascular cells, autonomic neurons, and immune cells. These cardiac non-myocytes play important roles in cardiac homeostasis and disease, yet the effect of hyperglycaemia and hyperlipidaemia on these cell types is often overlooked in preclinical models of diabetic cardiomyopathy. The advent of human-induced pluripotent stem cells provides a new paradigm in which to model diabetic cardiomyopathy as they can be differentiated into all cell types in the human heart. This review will discuss the roles of cardiac non-myocytes and their dynamic intercellular interactions in the pathogenesis of diabetic cardiomyopathy. We will also discuss the use of sodium-glucose cotransporter 2 inhibitors as a therapy for diabetic cardiomyopathy and their known impacts on non-myocytes. These developments will no doubt facilitate the discovery of novel treatment targets for preventing the onset and progression of diabetic cardiomyopathy.

Keywords

Diabetic cardiomyopathy • Cardiomyocytes • Endothelial cells • Autonomic neurons • Cardiac fibroblasts • Immune cells

1. Introduction

Diabetes mellitus is a growing global pandemic, representing a significant cause of morbidity and mortality around the world.^{1,2} A recent meta-analysis estimated that diabetes mellitus affected 463 million people worldwide in 2019, and the number of patients with diabetes mellitus is expected to increase to 629 million by 2045.³ Diabetes is a sustained condition of elevated blood glucose levels and is an umbrella term encompassing Type 1, Type 2, and gestational diabetes mellitus. Type 1 diabetes is an autoimmune-mediated disorder that results from T cell-mediated destruction of β -cells in the pancreas, leading to an insulin deficiency.⁴ Type 2 diabetes mellitus (T2DM) is a highly

complex, multisystem disorder, which is characterized by overt hyperglycaemia because of insulin resistance, impaired insulin secretion, and increased hepatic glucose output.⁵ Gestational diabetes is a pregnancy complication in which women with no known risk factors and without previously diagnosed diabetes develop hyperglycaemia, and its incidence is on the rise in recent decades.⁶ Among the three types of diabetes, T2DM accounts for 85–95% of all cases.

T2DM is a complex systemic disorder that can be attributed to a combination of genetic and environmental risk factors. Risk factors such as age, increased adiposity, sedentary lifestyle, smoking, and perturbed gut microbiome have been shown to cause hyperglycaemia and hyperlipidaemia in T2DM.^{7,8} At the community level, urbanization

* Corresponding author. E-mail: jlees@svi.edu.au

† Joint senior authors.

© The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

in developed and developing countries has cultivated sedentary behaviour and an obesogenic environment with inexpensive high sugar and high-fat diets, which have fuelled the T2DM epidemic.³ In some cases, individuals with a specific variation in T2DM-associated genes are more susceptible to the development of T2DM. A single nucleotide polymorphism in the *TCF7L2* gene identified by a genome-wide association study, which encodes a protein that regulates insulin production, predisposes individuals to T2DM.^{9,10}

2. Pathophysiological processes of T2DM

Blood glucose homeostasis is monitored by the pancreatic islet β -cells and regulated by insulin action on the target cells.¹¹ In the insulin signalling cascade, the insulin receptor substrate-1 is a crucial docking molecule for the insulin receptor, and its activation promotes the translocation of the glucose transporter to the cell membrane.¹² In T2DM, the functions of the insulin receptor and insulin receptor substrate-1 in glucose uptake are reduced, which is known as insulin resistance. This is mainly attributed to mitochondrial dysfunction, inflammation, ectopic lipid accumulation, and endoplasmic reticulum stress in the insulin target cells eventually leading to the development of hyperglycaemia.^{1,13} Insulin resistance-induced hyperglycaemia triggers β -cells to intensify their synthesis and secretion of insulin to overcome insulin resistance and restore glucose homeostasis.¹¹ However, this compensatory hyperinsulinaemia eventually causes the pancreatic β -cells to progressively lose their capacity to produce a sufficient amount of insulin to offset the peripheral insulin resistance.^{14,15} Hence, persistent impaired insulin action, together with chronic β -cell dysfunction, marks the clinical diagnosis of overt T2DM.

Overt hyperglycaemia is the core characteristic of T2DM and a potent risk factor for diabetes-related complications in the late stage of the disease.¹ An important group of diabetes-related complications are vascular complications, which can be further classified into microvascular and macrovascular complications.¹⁶ Microvascular complications comprise diabetes-related retinopathy, nephropathy, and neuropathy.¹⁶ T2DM patients are at 10–20 times higher risk of developing microvascular disorders,¹⁷ which arise from hyperglycaemia-induced thickening of capillary basement membranes.¹⁸ The underlying mechanism of microvascular complications includes the production of advanced glycation end-products (AGEs), activation of the polyol pathway, low-grade inflammation, and increased endoplasmic reticulum stress.¹⁹ On the other hand, insulin resistance and hyperglycaemia can also promote atherosclerosis and cause macrovascular complications including coronary artery disease, stroke, and peripheral vascular disease which are 2–4 times more likely in T2DM patients.^{16,17} Independent of these macrovascular complications, diabetes mellitus can cause impairments to cardiac structure and function and has long been known to increase the risk of heart failure.²⁰

3. Diabetic cardiomyopathy

Over one million Australians have T2DM, just over half of whom will die from cardiovascular disease, and even more will have serious but non-fatal cardiovascular complications.²¹ Indeed, adults with T2DM are 2–4 times more likely to experience heart failure than adults without diabetes.²² Heart failure caused specifically by diabetes, in the absence of other conditions such as ischaemic heart disease and hypertension, is

called diabetic cardiomyopathy, for which there are currently no effective treatments. The development of heart failure in T2DM patients is usually attributed to macrovascular disease, leading to heart failure with reduced ejection fraction (HFrEF, ejection fraction < 50%).²³ However, the development of heart failure independent of macrovascular complications is gaining attention, known as heart failure with preserved ejection fraction (HFpEF).^{24,25} The early manifestations of diabetic cardiomyopathy include left ventricular concentric hypertrophy, increased filling pressures, and impaired diastolic function, yet ejection fraction remains >50%, which resembles the cardiac phenotype of HFpEF.²⁶ This cardiac phenotype may be followed by further impairment of diastolic function and the onset of systolic dysfunction, resembling HFrEF.²⁶ While patients with diabetic cardiomyopathy often present with HFpEF, differences in sex-bias and the incidence and different manifestations of hypertrophy suggest that it would be naïve to view diabetic cardiomyopathy as just another manifestation of HFpEF.²⁷ Indeed, the clinical manifestations of diabetic cardiomyopathy are still not completely understood, and the mechanisms underlying the disease progression from HFpEF to HFrEF are unclear.^{28,29} This knowledge gap has impeded the development of effective treatments for diabetic cardiomyopathy. Therefore, it is important to develop a greater molecular and cellular understanding of pathophysiological phenotypes and disease progression in diabetic cardiomyopathy using clinically relevant disease models.

3.1 Sex differences

In non-diabetic patients, the risk of cardiovascular disease is higher in men. However, diabetes completely reverses this sex difference, and in diabetic patients the risk of cardiovascular disease is higher in women.^{30–32} Even in diabetic patients with comparable glycaemic control, an increased cardiovascular risk factor profile is reported in diabetic women relative to men.³³ For example, the added risk of heart failure associated with diabetes is five-fold higher in diabetic women compared with just 2.4-fold higher in diabetic men.³⁴ The increased risk of heart failure may be related to the heightened susceptibility of women with newly diagnosed T2DM to pathogenic remodelling of the left ventricle and reduced myocardial energy efficiency.³⁵ In streptozocin-induced mouse models of diabetic cardiomyopathy, despite no differences in cardiac structure between males and females, diabetic females are more susceptible to diastolic dysfunction despite exhibiting a lower extent of hyperglycaemia than males.³⁶ Cardiovascular complications including fibrosis, atherosclerosis, and endothelial dysfunction are also differentially regulated by sex in diabetes.³⁷ For example, diabetic women are more prone to endothelial dysfunction,^{38,39} and several markers of endothelial dysfunction are female-specific and independent of age or body mass index including plasminogen activator inhibitor-1, intercellular adhesion molecule-1, and E-selectin levels.^{40,41} Furthermore, endothelial dysfunction and insulin resistance are associated with worse cardiovascular outcomes in women than men with Type 1 or Type 2 diabetes.^{40,41} Sex differences have also been reported in mouse models of Type 1 diabetic cardiomyopathy,⁴² and in mitochondrial fusion and fission proteins in the foetal rat heart of offspring born to diabetic mothers.⁴³

4. Current understanding of the mechanisms underlying diabetic cardiomyopathy

Despite a wealth of studies on diabetic cardiomyopathy, our understanding of its pathogenesis remains elusive. Driven by reduced insulin




Figure 1 The contribution of non-cardiac tissues to the pathogenesis of diabetic cardiomyopathy. In diabetes, pancreatic beta-cell dysfunction and insulin resistance lead to impaired insulin-mediated glucose uptake and increased ectopic lipid accumulation in various non-cardiac tissues, including liver, adipose tissue, and skeletal muscle. Impaired insulin signalling in the liver increases hepatic glucose production, while glucose disposal in skeletal muscle is reduced, both of which contribute to systemic hyperglycaemia. To compensate for hyperglycaemia, the pancreas produces more insulin leading to hyperinsulinaemia. Furthermore, increased lipolysis of adipose tissue increases the levels of circulating free fatty acids leading to lipotoxicity and hyperlipidaemia. These pathological events result in overproduction of pro-inflammatory adipokines, dysregulation of hepatokines, and a reduction in protective myokines, all of which contributes to the pathogenesis of diabetic cardiomyopathy.

signalling and/or insulin resistance in adipose tissue, liver, and skeletal muscle, pathological changes in these non-cardiac tissues contribute to the development and progression of diabetic cardiomyopathy (Figure 1). Additionally, abnormal cardiac extracellular matrix deposition, diabetes-induced metabolic disturbance, oxidative stress, and inflammation, can all contribute to adverse cardiac remodelling and contractile dysfunction.^{5,44}

4.1 The role of adipose tissue in diabetic cardiomyopathy

Adipose tissues store excess energy and act as an endocrine organ to modulate the function of other organs via adipose tissue-derived signalling molecules called adipokines.⁴⁵ Adipose tissue is classified by morphology (white, beige, or brown) and location (subcutaneous, kidneys, breast tissue, bone marrow, epicardium/visceral pericardium).⁴⁶ Excessive expansion of adipose tissue, especially in the visceral pericardium, is a risk factor for both T2DM and diabetic cardiomyopathy.^{47–51} Obesity drives hypertrophy of white adipocytes, fibrosis, and insulin resistance, all of which lead to reduced lipid retention in the adipocytes and ectopic lipid accumulation in other organs including the liver and skeletal

muscle. Ectopic lipid accumulation is observed in CCN5 knockout obese mice⁵² and high-fat diet-fed rodents,^{53,54} which also display insulin resistance and cardiac hypertrophy. In human, healthy hearts transplanted into patients with T2DM show progressive lipid accumulation in cardiomyocytes within 12 months post-transplantation.⁵⁵ This might suggest that ectopic lipid accumulation may be one of the earliest pathologies in the development of diabetic cardiomyopathy.

The heart is surrounded by epicardial adipose tissue, which plays important roles in directing the cell fate of non-myocytes and maintaining myocardial metabolic homeostasis.⁵⁶ With a higher basal rate of fatty acid metabolism and lipogenesis than subcutaneous and visceral adipose tissue, epicardial adipose tissue provides energy to the underlying myocardium and acts as reservoir for excess fatty acids.⁵¹ The pathological expansion of epicardial adipose tissue has a well-documented association with cardiometabolic diseases, including diabetic cardiomyopathy,^{49,57–61} mediated by dysregulated production of pro-inflammatory cytokines and adiponectin from epicardial adipose tissue.⁴⁶ Epicardial adipose tissue also modulates cardiac endothelial function through its direct contact with the myocardium and the coronary arteries.^{62,63} In an ex vivo model of T2DM, human epicardial adipose tissue treated with diabetic conditions increased the expression of pro-inflammatory cytokines, such as

TNF- α and interleukin (IL)-1 β , which subsequently induced human coronary artery endothelial cells to acquire an inflammatory phenotype and reduced angiogenic potential.⁶⁴

4.2 The role of liver in diabetic cardiomyopathy

Individuals with a high fatty liver index and advanced liver fibrosis are associated with an increased risk of myocardial infarction, heart failure, and cardiovascular mortality.^{65–67} Chronic liver conditions such as non-alcoholic fatty liver disease (NAFLD) can negatively affect cardiovascular system via secretion of hepatocyte-derived cytokines, known as hepatokines.⁶⁸ For example, serum fibroblast growth factor-21 predominantly produced and secreted by hepatocytes, is positively correlated with metabolic syndrome and the severity of liver fibrosis in T2DM patients.^{69,70} The hepatokine fetuin-A has been shown to mediate cross-talk between the liver and the heart, preventing blood vessel calcification and aortic stenosis. A lower fetuin-A concentration is associated with greater risk of microvascular and macrovascular complications in T2DM patients.⁷¹ Interestingly, individuals with T2DM and NAFLD often present with a cardiac autonomic nervous system imbalance, displaying an increase in sympathetic tone,^{72,73} which is associated with increased blood pressure and risk of ventricular arrhythmia in T2DM.^{74–76}

4.3 The role of skeletal muscle in diabetic cardiomyopathy

The skeletal muscle is the primary site of glucose disposal, making it a pivotal player in the development of insulin resistance.⁷⁷ Insulin resistance in skeletal muscle stems from excessive lipid accumulation following saturation of adipose tissues, which impairs insulin receptor signalling and glucose uptake. Similar to the liver and adipose tissues, skeletal muscle establishes communication with other tissues and organs via secreted soluble proteins known as myokines such as myosin, myostatin, IL-6, IL-13, IL-15, and irisin.^{78,79} Physical inactivity has been shown to alter the secreted myokine profile, establishing a firm link between a sedentary lifestyle and several metabolic disorders.^{80–82} The therapeutic effects of myokines in diabetic cardiomyopathy have received some attention. In streptozotocin-treated mice, the overexpression of the myokine osteonin prevented cardiomyocyte apoptosis and myocardial fibrosis by restoring cardioprotective proteasomal activity.⁸³ The myokine irisin has gained increasing attention with respect to its role in the development of T2DM and diabetic cardiomyopathy.⁸⁴ Circulating levels of irisin have been shown to be reduced in newly diagnosed diabetic patients⁸⁵ and in T2DM *db/db* mice.⁸⁶ Excitingly, restoring the irisin levels with either intramyocardial injection of adenovirus encoding irisin or treatment with recombinant human irisin effectively attenuated cardiac diastolic dysfunction and adverse structural remodelling in *db/db* mice.⁸⁶ *In vitro* rat cardiomyocytes treated with diabetic culture conditions lose expression of irisin, while overexpression of irisin alleviates the acquired inflammatory response, reduces oxidative stress and cardiomyocyte apoptosis, and improves mitochondrial function.^{86,87} Collectively, these studies highlighted the cardioprotective effect of myokine irisin in the setting of diabetes.

4.4 Abnormal cardiac extracellular matrix deposition

Hyperglycaemia and insulin resistance promote cardiac fibrosis. Patients with diabetic cardiomyopathy usually present with left ventricular hypertrophy and perivascular fibrosis.^{88–90} Hyperglycaemia induces

overproduction of extracellular matrix proteins such as collagens from cardiac fibroblasts.⁹¹ Cardiac fibroblasts also play a physiological role in maintaining extracellular matrix homeostasis through balancing the activities of matrix metalloproteinases and tissue inhibitors of metalloproteinases.⁹² Matrix metalloproteinases induce the degradation of the extracellular matrix, but their activity is attenuated under systemic hyperglycaemia causing the overaccumulation of extracellular matrices.⁹³ This is attributed to hyperglycaemia-mediated promotion of the non-enzymatic formation of AGEs, which can cross-link with the extracellular matrices and increase their resistance to the proteolytic action of matrix metalloproteinases.⁹³ AGEs can also promote the differentiation of fibroblasts to myofibroblasts, which secrete pro-fibrotic cytokines and promote excessive extracellular matrix deposition.⁹⁴ The pro-fibrotic activity of fibroblasts and myofibroblasts is further exacerbated by growth factors such as transforming growth factor β -1 (TGF β -1), connective tissue growth factor, and various ILs, all of which are up-regulated in the diabetic myocardium.⁹⁴ This combination results in excessive deposition of extracellular matrix and contributes to increased cardiac stiffness and reduced cardiac compliance, which are the classical hallmarks of the early stage of diabetic cardiomyopathy.^{44,95} Indeed, the degree of extracellular matrix deposition has been shown to be correlated with mortality and hospitalization for heart failure in patients with T2DM.⁹⁶

4.5 Diabetes-induced impaired cardiac metabolism

The heart has a high metabolic rate relative to other tissues.⁹⁷ The majority of energy in the form of adenosine triphosphate (ATP) in cardiomyocytes is produced via mitochondrial oxidation of substrates such as fatty acids (60–70%), glucose (20%), and lactate (10%).⁹⁸ The ability of cardiomyocytes to utilize a selection of substrates for ATP production is known as metabolic flexibility; this is impaired in diabetic cardiomyopathy.⁹⁹ The reduced insulin signalling and reduced glucose uptake in cardiomyocytes shift metabolism from glucose to fatty acid oxidation.¹⁰⁰ In addition, suppression of insulin activity induces the activity of lipases in adipose tissue and the secretion of very-low-density lipoprotein in the liver, resulting in an increased level of free fatty acids in the circulation.¹⁰¹ These free fatty acids can be taken up by the liver and converted into ketone bodies, which provides additional metabolic fuel for extrahepatic tissues, including the heart. While studies have reported increased ketone body utilization in failing diabetic hearts as a compensatory mechanism for metabolic inflexibility,^{102,103} a recent study by Brahma *et al.*¹⁰⁴ has demonstrated contrasting results, in which diabetic-induced hyperglycaemia suppressed myocardial ketolytic capacity and ketone body catabolism. Nevertheless, the net increase and accumulation of ketone bodies in the circulation increase the risk of diabetic ketoacidosis.¹⁰⁵

The high levels of circulating free fatty acids can also increase the activity of peroxisome proliferator-activated receptors on cardiomyocytes, specifically the α subtype, which promote the expression of proteins involved in fatty acid uptake and oxidation such as fatty acids translocase, carnitine palmitoyltransferase-1, and long-chain acyl coenzyme A dehydrogenase.¹⁰⁶ The adenine nucleotide transporter that transports ATP from the mitochondria to the cytosol has been shown to be inhibited by long-chain acyl coenzyme A derivatives and as a consequence, impairs myocardial contractility.^{107–109} Excessive uptake of fatty acids by the cardiomyocytes promotes the futile recycling of the lipid intermediates as a protective mechanism towards lipotoxicity.¹¹⁰ However, when the delivery of fatty acids exceeds the capacity of fatty

acid oxidation these un-oxidized fatty acids can be directed into lipid metabolism pathways that synthesis triacylglycerols, ceramides, and diacylglycerols.¹¹¹ Although triacylglycerols have a cardioprotective effect by preventing the excessive generation of reactive lipid intermediates, ceramides and diacylglycerols can activate signalling pathways leading to the development of cardiac lipotoxicity.¹¹² In essence, alongside pre-existing insulin resistance, cardiomyocytes subjected to a hyperlipidaemic environment exhibit impaired metabolic flexibility, favouring beta oxidation of fatty acids and the production of reactive lipid intermediates.

4.6 Cardiac oxidative stress

Oxidative stress, the result of imbalanced generation and scavenging of reactive oxygen species (ROS) and reactive nitrogen species is another mechanism in the development of diabetic cardiomyopathy.¹⁰⁶ In T2DM, the primary source of ROS in cardiomyocytes is superoxide produced from up-regulation of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, mitochondrial dysfunction, and uncoupling of nitric oxide (NO) synthase.^{113,114} Additionally, the endogenous antioxidant system is impaired in T2DM, which further exacerbates cardiac oxidative stress. For example, the expression of nuclear factor erythroid 2-related factor 2 (Nrf2), which is required to initiate the antioxidant response, is down-regulated in high-fat diet-induced T2DM mouse and rat models.^{115,116} The overproduction of ROS also activates multiple pathological signalling cascades including protein kinase C and c-Jun N-terminal kinase pathways, which create a detrimental feed-forward loop inducing further ROS generation.^{117,118} Peroxynitrite is a potent oxidant formed through a reaction between superoxide and NO.¹¹⁹ The formation of peroxynitrite can directly degrade myofibrillar protein and DNA, and reduce NO bioavailability, which itself is implicated in the pathophysiology of diabetic cardiomyopathy.¹²⁰ Finally, apart from damaging proteins and DNA, the accumulation of ROS in cardiomyocytes also initiates a maladaptive inflammatory response, detailed below.

4.7 Cardiac inflammation

T2DM is now recognized as an inflammatory disorder.¹²¹ Several *in vitro* and *in vivo* diabetic models have reported increased expression of pro-inflammatory factors such as tumour necrosis factor- α , IL-1 β , IL-6, and NLR Family Pyrin Domain Containing 3 (NLRP3) inflammasomes in cardiomyocytes, all of which correlate with pathological cardiac remodelling such as fibrosis and hypertrophy.^{87,122–124} Cardiac inflammation in T2DM is in part mediated by ROS-induced activation of NLRP3 inflammasomes, which can lead to a cascade of signalling events that initiate cardiomyocyte apoptosis and myocardial fibrosis.²⁷ Apart from NLRP3 inflammation, circulating AGEs and pro-inflammatory cytokines can activate other pro-inflammatory pathways in cardiomyocytes such as nuclear factor kappa-B expression and lipoxygenases which contribute to the development of diabetic cardiomyopathy.^{125–127} Tumour necrosis factor- α and IL-1 β have been shown to increase Ca²⁺ leakage from cardiomyocyte sarcoplasmic reticula contributing to depressed systolic Ca²⁺ transients and resulting in cardiac contractile dysfunction and arrhythmia.¹²⁸ Collectively, the inflammatory responses induced by the systemic and local changes during T2DM are diverse, and the pro-inflammatory pathways are often related and can contribute to the pathophysiology of diabetic cardiomyopathy by promoting myocardial remodelling and impairing cardiac function.

5. The involvement of cardiac non-myocytes in the pathogenesis of diabetic cardiomyopathy

Hyperglycaemia, hyperlipidaemia, and systemic changes such as increased circulating pro-inflammatory cytokines, AGEs, and ROS are the drivers for maladaptive signalling pathways in cardiomyocytes, contributing to the development of diabetic cardiomyopathy.^{27,129} However, the pathophysiology of diabetic cardiomyopathy cannot be attributed to the pathological changes of the cardiomyocytes alone. Indeed, the heart is a complex 3D structure with heterogeneous cell populations including cardiomyocytes, cardiac fibroblasts, coronary vasculature, autonomic neurons, and immune cells.¹³⁰ The cardiac non-myocyte cell populations play an important role in regulating electrical, chemical, and biomechanical signalling in the heart and form an extensive network of intercellular communication to maintain cardiac homeostasis, as well as orchestrate the pathogenesis of diabetic cardiomyopathy (Figure 2). Indeed, microvascular complications and neurocardiac dysfunction are often reported in T2DM patients, suggesting the involvement of non-myocyte cell populations in the disease. However, the effect of T2DM on cardiac non-myocytes such as the cardiac vasculature, autonomic neuronal function, and its consequences remain poorly understood.^{131,132}

5.1 The role of cardiac fibroblasts in diabetic cardiomyopathy

Cardiac fibroblasts represent ~20% of the non-cardiomyocytes in the heart and are responsible for extracellular matrix deposition, maintenance, and remodelling.¹³³ The myocardial extracellular matrix is vital in maintaining healthy cardiac structure and function by serving as a scaffold for the myocytes and non-myocytes populations. This scaffold allows transmission of electrical conduction between cardiomyocytes as well as transduction of mechanical forces throughout the myocardium and can prevent injury resulting from over-extension.^{94,134}

The number of cardiac fibroblasts in the mouse heart doubles as a result of T2DM.¹³⁵ In response to hyperglycaemia, cardiac fibroblasts up-regulate and remodel cardiac extracellular matrix components, causing fibrosis and contractile dysfunction.¹³⁶ Impaired left ventricle compliance and diastolic dysfunction is largely attributed to increased matrix accumulation in ~50% of T2DM patients.¹³⁷ Hyperglycaemia has been shown to increase collagen production in neonatal and adult animal and human cardiac fibroblasts *in vitro* and *in vivo*. This contributes to exaggerated extracellular matrix deposition and can disrupt electrophysiological communication between cardiomyocytes.^{134,138–143} Moreover, increased fibrosis within the perivascular regions could form a physical barrier to oxygen and nutrient diffusion and subsequently reduce their availability to the myocardium causing focal ischaemia.^{144,145} Excessive matrix synthesis is largely driven by myofibroblasts in T2DM for which several hyperglycaemia-modulated pathways have been identified that might promote the activation of a pro-fibrotic cardiac fibroblast phenotype. Detailed molecular mechanisms of diabetic fibrosis have been recently reviewed.¹³⁴

In addition to extracellular matrix modulation, cardiac fibroblasts can also influence cardiac electrical signalling and conduction through the expression of gap junctions, ryanodine receptors, and ion channels such as voltage-gated potassium channel and voltage-dependent calcium




Figure 2 Cellular interactions among non-myocytes in the heart and their pathological phenotypes in T2DM. Non-myocytes populations play important roles in maintaining healthy cardiac function and promoting cardiomyopathy under diabetic conditions. Cardiac fibroblasts receive pro-fibrotic factors from immune and vascular cells to regulate the dynamics of the extracellular matrix. Conversely, cardiac fibroblasts can induce angiogenesis and infiltration of immune cells to evoke an inflammatory response via secretion of angiogenic growth factors and chemoattractants, respectively. The function of autonomic nervous system is tightly linked with the activity of the immune cells, where the modulation of neuronal activity can be achieved by pro-inflammatory cytokines. Under diabetic conditions, these intercellular interactions can be exacerbated resulting in maladaptive cellular phenotype (highlighted in boxes) and contribute to the pathogenesis of diabetic cardiomyopathy. Signalling molecules include proteins, EVs, messenger RNA (mRNA), microRNA (miRNA), long non-coding RNA (lncRNA), and circular RNA (circRNA).

channel $\text{Ca}_v1.2$.^{128,146,147} Although cardiac fibroblasts are non-excitable cells, they exhibit high membrane resistance and are able to conduct electrical signals.⁹⁴ Cardiac fibroblasts can electrically couple to each other and to adjacent cardiomyocytes via gap junctional connexins (Cx40, Cx43, and Cx45) to modulate their electrophysiological properties. Alteration of these gap junctional communications can lead to arrhythmia and has been implicated in various pathological conditions including diabetic cardiomyopathy.^{94,148} Moreover, abnormal calcium signalling increases the susceptibility to cardiac arrhythmia and mitochondrial calcium handling is impaired in the diabetic heart, partly attributed to oxidative stress-induced dysfunction of the ryanodine receptors and SERCA2 protein.^{128,149,150} However, whether calcium handling protein function and ion channels in cardiac fibroblasts and myofibroblasts are also altered in diabetic conditions and contribute to diabetic cardiomyopathy remains unclear.

Cardiac fibroblasts can also interact with endothelial cells to regulate angiogenesis and contribute to vascular remodelling following cardiac injury.⁹⁴ Fibroblasts have been shown to interact with endothelial cells indirectly via secretion of pro-angiogenic growth factors such as fibroblast

growth factor and vascular endothelial growth factor, and anti-angiogenic pigment epithelium-derived growth factor.^{94,151} Cardiac fibroblasts could also directly contribute to cardiac angiogenesis by undergoing mesenchymal-to-endothelial transition and adopt an endothelial cell fate as demonstrated in subjects with ischaemic heart disease.¹⁵² Whether this phenomenon is also observed in the setting of diabetic cardiomyopathy, however, remains to be investigated. Furthermore, cardiac fibroblasts are the main source of pro-inflammatory cytokines such as $\text{IL-1}\beta$ following injury and have been shown to promote cardiac infiltration of inflammatory cells through secretion of the chemokine CXCL10 and contribute to the cardiac inflammation in diabetes.^{94,153,154}

5.2 The role of coronary vasculature in diabetic cardiomyopathy

The coronary vasculature is crucial for maintaining perfusion to the myocardium. Within the coronary vasculature, endothelial cells form a continuous semipermeable biological membrane that regulates the

exchange of oxygen, nutrients, and waste between the circulatory system and the myocardium.¹⁵⁵ Endothelial cells also provide energy substrates for neighbouring cardiomyocytes.¹⁵⁶ Under physiological conditions, endothelial cells primarily utilize ATP generated from glycolysis, whereas fatty acids are primarily used to synthesize nucleotides or transported to the cardiomyocytes.¹⁵⁶ However, in hyperglycaemic conditions, endothelial cells initiate a protective mechanism to prevent the entry of glucose into cardiomyocytes by reducing the expression of glucose transporter-1 at the interface between the endothelial cells and the cardiomyocytes. This, in turn, leads to the accumulation of intracellular glucose in endothelial cells, where glucose is shunted into alternative pathways such as the polyol and hexosamine biosynthesis pathways to reduce glycolytic flux.¹⁵⁷ The net result is the production of ROS and AGEs that promote endothelial cell dysfunction.¹⁵⁸

With their close proximity to the cardiomyocytes, any dysfunction in endothelial cells can have a direct impact on myocardial function and potentially contribute to the progression of diabetic cardiomyopathy. Indeed, T2DM patients without obstructive coronary artery disease often experience substantial impairment of coronary microvascular function caused by hyperglycaemia-induced ROS and protein kinase C activation in endothelial cells.¹⁵⁹ The hallmark of endothelial dysfunction has reduced NO bioavailability. Similar to cardiomyocytes, hyperglycaemia can activate NADPH oxidase and uncouple endothelial NO synthase (eNOS) in endothelial cells, resulting in oxidative stress and reduced NO bioavailability, respectively.^{119,160,161} In addition, the uncoupling of eNOS causes its isomeric switch from NO-producing eNOS dimers to a superoxide-producing eNOS monomer, further contributing to oxidative stress.¹¹⁹ The reduction of NO bioavailability is also associated with the development of diastolic dysfunction through up-regulation of fibrotic signalling and phosphorylation of the contractile protein titin, resulting in increased myocardial stiffness and cardiac hypertrophy.¹⁶² Several other pathological endothelial mechanisms contribute to fibrosis in the pathogenesis of diabetic cardiomyopathy. In the diabetic heart, the endothelium produces endothelin-1, a pro-fibrotic agent which contributes to chronic inflammation in a negative feedback loop,¹⁶³ while endothelial-specific disruption of endothelin-1 can reduce cardiac fibrosis.^{164,165} Endothelial cells also contribute to diabetic cardiac fibrosis through the process of endothelial-to-mesenchymal transition, in which endothelial injury leads to transition to a myofibroblast-like phenotype. Endothelial-to-mesenchymal transition is widely reported in models of diabetic cardiomyopathy and is regulated by a variety of signals including miR-18a-5p/Notch2,¹⁶⁶ miR-200b,¹⁶⁷ Sirt6/Notch1,¹⁶⁸ and kallikrein-related Peptidase 8.¹⁶⁹

While endothelial cells are regarded as the primary vascular cell type involved in the pathology and pathogenesis of diabetic cardiomyopathy,^{119,161} vascular smooth muscle cells (VSMCs) and pericytes may also contribute to the disease pathogenesis. The diabetic milieu of hyperglycaemia, hyperinsulinaemia, and hyperlipidaemia has been shown to perturb VSMC contractile function and induce the pathological and highly proliferative VSMC synthetic phenotype.^{170–173} Aortic VSMCs from *db/db* mice overexpress miR-504 which inhibits contractile gene expression, promotes the synthetic phenotype, and increases proliferation and migration.¹⁷³ Diabetic hyperglycaemia and hyperlipidaemia have been shown to directly affect the contractile function of VSMCs via inflammation-induced modulation of the microRNA (miRNA)-connexin/Rho kinase regulatory pathway,¹⁷⁰ while hyperglycaemia-induced telomerase activity and nuclear factor kappa-B expression have been linked to their increased proliferation and invasion.^{171,174} In human T2D induced pluripotent stem cell (iPSC)-derived VSMCs, perturbed lipid assembly was linked to VSMC

pathogenic proliferation and migration, in which overexpression of the esterase arylacetamide deacetylase was found to be cardioprotective, reducing the number of atherosclerotic lesions.¹⁷⁵

Pericytes envelop the endothelial layer of small vessels and stabilize the microvasculature. Pericytes are abundant in the myocardium making up ~5% of non-myocytes,¹³³ where they secrete pro-angiogenic factors such as vascular endothelial growth factor and TGF β , affect vascular tone, and contribute to basement membrane thickening.^{176,177} Pericyte loss is considered an early sign of microvascular diseases and is observed in diabetic nephropathy and diabetic retinopathy,^{177,178} although their role in diabetic cardiomyopathy is still unclear. Diabetic patients with end-stage HF have reduced numbers of myocardial capillaries and pericytes, accompanied by increased myocardial stiffness and loss of contractile function.¹⁷⁹ Pericyte loss can occur through detachment caused by inflammatory endothelial activation¹⁸⁰ or migration of the vessel,¹⁸¹ while the capacity for endothelial cells to attract pericytes to sites of neovascularization is reduced in hyperglycaemic conditions.¹⁷⁹ Notably, sodium-glucose cotransporter-2 (SGLT2) inhibitors can reverse renal and retinal pericyte dysfunction induced by hyperglycaemia,^{182,183} which raises the interesting hypothesis that the beneficial effects of SGLT2 inhibitors on HF may be partially attributable to their direct actions on the cardiac microvasculature.¹⁸⁴

5.3 The role of autonomic neurons in diabetic cardiomyopathy

The sympathetic and parasympathetic nervous systems serve to regulate bodily functions such as the respiratory rate, digestion, and heart rate.¹⁸⁵ In the heart, sympathetic and parasympathetic neurons release the neurotransmitters noradrenaline and acetylcholine, respectively, to regulate cardiac function.^{185,186} Cardiac autonomic dysfunction is a recognized diabetic complication that damages the heart and increases the risk of developing arrhythmias.^{187,188} The prevalence of cardiac autonomic neuropathy (CAN) in human T2DM ranges from 25 to 75% due to the variable criteria used.¹⁸⁹ Hyperglycaemia-associated injury of the autonomic nerves via ROS and toxic glycosylation products is thought to be the primary cause of CAN beginning with parasympathetic denervation followed by sympathetic denervation and relative sympathetic dominance.¹⁹⁰ Recently, six phosphatidylcholine and two sphingomyelin lipid metabolites were also linked to the development of CAN in recent-onset T2DM.¹⁹¹ In several clinical studies, patients with chronic T2DM demonstrated symptoms of CAN such as high resting heart rate, decreased heart rate variability, and autonomic denervation.^{131,188,192,193}

Hyperglycaemia-associated injury of sympathetic nerves represents the most common cause of sympathetic neuropathy, leading to contractile dysfunction of the cardiomyocytes.^{186,194} In animal models, investigations of hyperglycaemia-induced sympathetic dysfunction have usually employed an indirect approach by studying the cardiomyocytes rather than the sympathetic neurons. Studies have focused on the expression and function of cardiomyocyte β -adrenergic receptors, which recognize noradrenaline released from sympathetic neurons, and their downstream pathways under the conditions of hyperglycaemia and insulin resistance.^{195,196} For example, mice fed with a high-fat diet exhibit reduced cardiac sensitivity towards β -adrenergic stimulation by noradrenaline and contractile dysfunction such as increased cardiac stiffness and diastolic dysfunction.^{195,196}

Autonomic neurons may also interact with cardiac vascular cells in the development of diabetic cardiomyopathy. The sympathetic co-transmitter neuropeptide Y can be found in cardiovascular neurons supplying the vasculature and cardiomyocytes.¹⁹⁷ In T2DM, the expression

of neuropeptide Y receptors and its activity on endothelial cells are reduced thereby blunting angiogenesis.¹⁹⁸ In rat models of streptozotocin-induced diabetes, there are increased cardiac levels of both noradrenalin and acetylcholine by 8 weeks.^{199,200} Excessive levels of circulating catecholamines generate oxidative products which can induce Ca^{2+} -overload in VSMCs and contribute to microvascular disease.¹³² Given that CAN in the setting of T2DM appears to be associated with the development of diabetic cardiomyopathy and increased risk of mortality,¹⁸⁷ it will be of great importance to further understand the interactions between cardiac autonomic neurons and other non-myocytes in the development of diabetic cardiomyopathy.

5.4 The role of immune cells in diabetic cardiomyopathy

Systemic inflammation is a key feature of T2DM,²⁰¹ and myocardial inflammation is a key process in the development of diabetic cardiomyopathy.^{202–204} In response to injury, the heart undergoes an early 'adaptive' inflammatory response as a remodelling and repair mechanism.²⁰⁵ However, excessive and sustained inflammation in response to a persistent stress such as diabetes, can impair this adaptive response and exacerbate cardiac injury.²⁰⁶ Diabetic conditions induce oxidative stress, the secretion of pro-inflammatory cytokines, leucocyte mobilization, and activation of NF- κ B, which work in a positive feedback loop to perpetuate inflammation.^{207,208} Leucocytes are the effectors of the immune system used to maintain tissue homeostasis.²⁰⁹ In diabetic cardiomyopathy, over-activation of NF- κ B increases the recruitment of leucocytes to the heart,^{135,210,211} which is associated with a higher risk of cardiovascular disease in diabetic patients.²¹² Leucocytes include neutrophils, monocytes, macrophages, lymphocytes, and platelets, among others.²¹³ Neutrophils, macrophages, and lymphocytes have known roles in diabetic cardiomyopathy.²¹² Neutrophils are the first responders and constitute the first line of defence at sites of inflammation. Following cardiac injury, neutrophils polarize macrophages towards a reparative M2 phenotype.²¹⁴ However, in diabetes, neutrophils have also been shown to secrete pro-inflammatory factors including peroxidases, cytokines, and neutrophil extracellular traps.^{215,216} Indeed, a higher neutrophil to lymphocyte ratio is an early and accurate indicator of subclinical diabetic cardiomyopathy.²¹⁷ Extracellular glucose levels profoundly impact macrophage metabolism and identity.²¹⁸ Diabetes-induced hyperglycaemia impairs macrophage phagocytosis,²¹⁹ reduces the release of lysosomal enzymes,²²⁰ and reduces chemotactic activity,²²¹ while reducing blood glucose levels has been shown to reverse these phenotypes in both rodents²²² and humans.²²³

The classification of macrophages has recently grown to encompass a spectrum of macrophage phenotypes between the inflammatory M1-like and the reparative M2-like phenotypes, and the roles of many of these in diabetic cardiomyopathy require further elucidation.^{224–227} In diabetes, the M1-like phenotype prevails promoting a persistent low level of inflammation and insulin resistance^{228,229} while M2 macrophages reduce cardiac inflammation.^{230–232} Hyperglycaemia induces an M1 phenotype by increasing the expression of long-chain acyl-CoA synthetase-1, which promotes lipid accumulation and lipotoxicity.^{233,234} In diabetic cardiomyopathy, AGEs polarize macrophages to an M1 pro-inflammatory phenotype through a mechanism involving miR-471-3p/SIRT1,²²⁹ while M2 macrophages secrete macrophage mannose Receptor 1 and IL-10, reducing myocardial fibrosis and cardiomyocyte hypertrophy.^{235,236} Efferocytosis, the engulfment of apoptotic cells and debris by macrophages, is also impaired in diabetes via reduced miR-126 expression and MerTK function, thereby

prolonging cardiac inflammation.^{209,237} In T2DM, cardiac inflammation and insulin resistance are also regulated by T-lymphocytes including T-helper (Th) and T regulatory (Treg) cells.²⁰⁹ Diabetes increases the number and proportion of Th1,²³⁸ Th17,²³⁹ and Th22 subtypes, which contributes to cardiac hypertrophy, fibrosis,²⁴⁰ and coronary artery disease.^{241–243} As their name suggests, Treg cells can regulate Th cells and the inflammatory response. In T2DM, Tregs can inhibit Th1, Th2, and Th17 responses to improve insulin resistance,²⁴⁴ and Treg/Th17 and Treg/Th1 ratios decline in diabetic cardiomyopathy.^{238,245} Balancing pro-inflammatory (Th1 and Th17) and regulatory (Treg) T cells may be a viable therapeutic approach to manage or prevent chronic cardiac inflammation.

In their interactions with other cardiac non-myocytes, cardiac immune cells can signal to cardiac fibroblasts to influence fibrosis and contribute to cardiac remodelling in diabetic cardiomyopathy. Inflammatory signals such as TNF α , IL-1 β , and TGF β can act directly on cardiac fibroblasts to promote fibrosis.¹⁶⁵ For example, TNF α stimulates cardiac fibroblast proliferation and collagen production via WISP1,²⁴⁶ while IL-1 β induces cardiac fibroblasts to release insulin-like growth factor-1 via STAT3 signalling to promote cardiomyocyte hypertrophy.²⁴⁷ TGF β , the primary pro-fibrotic cardiac cytokine secreted by macrophages, T-cells, and fibroblasts themselves, is responsible for fibroblast activation.^{95,204} Finally, injury-site macrophages can transition into fibroblast-like cells with profound ramifications for our understanding of the inflammation-healing-axis.²⁴⁸ Macrophage-to-myofibroblast transition has been observed in myocardial infarction,²⁴⁹ diabetic nephropathy,²⁵⁰ and a T2DM model of dermal wound healing,²⁵¹ but not yet reported in the context of diabetic cardiomyopathy. Notably, following myocardial infarction, cardiac macrophages can transition to a myofibroblast-like cell able to synthesize immature forms of collagen and elastin.²⁴⁹ However, these macrophage-derived myofibroblast-like cells do not respond to typical pro-fibrotic signals such as aldosterone, angiotensin II, or hypoxia, suggesting a different underlying mechanism and that new approach may be needed to combat their fibrotic activity.²⁴⁹ Interestingly, in the T2DM model of dermal wound healing, there was a reduced transition rate of myeloid cells to myofibroblasts and reduced wound collagen and skin stiffness which was rescuable via a miRNA-21 mimetic.²⁵¹ In the setting of diabetic cardiomyopathy, this may explain the prolonged retention of cardiac inflammatory macrophages which are unable to transition into their intended fibroblast state.

6. Extracellular vesicles mediate cellular and tissue crosstalk

In addition to soluble factors, intercellular transfer of extracellular vesicles (EVs) has emerged as an important paracrine mechanism for cells to communicate with nearby and distant cells. EVs are nano-sized lipid membrane-bound particles endogenously released from various cell types in the body. These nano-sized vesicles contain a range of bio-reactive materials (proteins, lipids, metabolites) and genetic material (DNA, messenger RNA, and non-coding RNAs) that are unique to each cell type and altered in disease states like T2DM. EVs are involved in many pathophysiological processes including cardiometabolic diseases.^{252,253} The contribution of EVs to the progression of diabetic cardiomyopathy has been comprehensively reviewed by others^{254,255} and will be briefly discussed here.

In T2DM patients, circulating endothelial cell-derived EVs are elevated, correlating with an increased risk of diabetes-related vascular complications and atherogenesis.^{256–258} Plasma EVs isolated from T2DM patients show aberrant miRNA expression profiles,^{259,260} while

intercellular crosstalk among cardiovascular system-related cells via secreted EVs has been implicated in various pathological processes including impaired angiogenesis, inflammation, myocardial hypertrophy, and fibrosis, all of which can lead to diabetic cardiomyopathy.²⁵⁵ For example, EVs isolated from diabetic subjects contain higher levels of anti-angiogenic miR-320, and lower levels of angiogenic miR-126 and vascular endothelial growth factor receptor-2.^{261–264} Transfer of miR-320 from cardiomyocyte-derived EVs to endothelial cells results in impaired angiogenesis.²⁶¹ Similarly, hyperglycaemia has been shown to up-regulate anti-angiogenic miR-503 expression in endothelial cell-derived EVs and functional transfer of miR-503 negatively affects pericyte migration and proliferation.²⁶⁵ In addition to miRNAs, EVs isolated from the plasma of diabetic subjects were shown to contain high levels of Arginase 1, which can cause vascular dysfunction when taken up by endothelial cells.²⁶⁶ Transfer of miR-21-3p-enriched EVs from cardiac fibroblasts to cardiomyocytes has been reported to induce cardiomyocyte hypertrophy through silencing of sorbin and SH3 domain-containing protein 2 and PDZ and LIM Domain 5,²⁶⁷ although whether this paracrine miRNA crosstalk is exacerbated by diabetes remains to be determined.

In addition to miRNAs, other non-coding RNAs such as long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs) are also known to play a significant role in the disease development and progression of diabetic cardiomyopathy, as reviewed comprehensively elsewhere.^{268–270} For example, lncRNA H19 expression was down-regulated in the myocardium of diabetic rats and high glucose-treated cardiomyocytes, and was functionally associated with cardiomyocyte apoptosis, oxidative stress, and cardiac muscle dysfunction.²⁷¹ In another study, lncRNA Kcnq1ot1 expression was found to be elevated in the myocardium of diabetic mice and high glucose-treated cardiomyocytes and cardiac fibroblasts, and was associated with fibrosis, inflammation, and pyroptosis.^{272,273} In addition to the myocardium, several dysregulated lncRNAs, such as E330013P06, Dnm3os (dynamin3 opposite strand), and Diabetes Regulated anti-inflammatory RNA, have been found in the immune cells of diabetic subjects.^{274–276} Up-regulation of lncRNA_E330013P06 in diabetic mouse macrophages has been shown to induce expression of pro-inflammatory genes and promote foam cell formation, which are major risk factors of atherosclerosis.²⁷⁵ Other lncRNAs that have been implicated in the pathogenesis of diabetic cardiomyopathy include HOTAIR,²⁷⁷ MALAT1,²⁷⁸ MIAT,^{279,280} CRNDE,²⁸¹ and TUG1,²⁸² among others.^{269,274} In regard to circRNAs, up-regulation of circRNA_000203 has been found in diabetic mouse myocardium and was associated with increased expression of pro-fibrotic genes in cardiac fibroblasts.²⁸³ Similarly, circRNA_010567 expression was found to be up-regulated in murine diabetic myocardium and implicated in myocardial fibrosis by sponging miR-141, which directly targets pro-fibrotic TGF- β 1.²⁸⁴

Most studies have only reported the roles of lncRNAs and circRNAs as intracellular signalling regulators of pathological mechanisms of diabetic cardiomyopathy. Indeed, there are only limited studies describing the intercellular transfer of these non-coding RNAs. Over 3350 circulating lncRNAs were shown to be dysregulated in the plasma of Type 2 diabetic mouse model with impaired cardiac function.²⁸⁵ In that study, the Top 5 networked lncRNAs XLOC015617, AK035192, Gm10435, TCR- α chain, and MouselncRNA0135 were involved in the development and motion of myofilaments, the immune response, and apoptosis.²⁸⁵ In serum from diabetic patients, lncRNA expression of TINCR²⁸⁶ and NKILA²⁸⁷ can be used to predict diabetic cardiomyopathy up to 6 months before a clinical diagnosis,²⁸⁷ indicating that circulating lncRNAs may be easily accessible serum biomarkers as well as therapeutic targets.

EVs also play a role in inter-organ crosstalk. Circulating EVs generated remotely by non-cardiac tissues in the diabetic milieu, have also been implicated in the development and progression of diabetes complications.^{288,289} EVs from visceral adipose tissues of high-fat diet-induced obese mice have been shown to reprogramme macrophages into the pro-inflammatory M1 phenotype and induce chronic atherosclerotic inflammation, a risk factor of diabetic cardiomyopathy, when delivered intravenously into hyperlipidemic apolipoprotein E-deficient mice.²⁹⁰ Similarly, EVs isolated from 3T3-L1 adipocytes subjected to simulated insulin resistance were enriched with sonic hedgehog protein and induced pro-inflammatory M1 polarization of macrophages via the Patched(Ptch)/PI3K signalling pathway.²⁹¹ Interestingly, EVs from adipose tissue macrophages of obese mice overexpressed miR-155, which targets peroxisomal proliferator-associated receptor γ and led to glucose intolerance and insulin resistance in other tissues such as muscle and liver when administered into lean mice.²⁹²

In the light of these findings, the cargo of EVs could potentially be engineered to deliver beneficial biomolecules as a new avenue for treating diabetes complications.^{289,293} Indeed, using streptozotocin-induced diabetic mice with cardiac-specific overexpression of Hsp20, Wang et al.²⁹⁴ have demonstrated that cardiomyocyte-specific EVs carrying overexpressed Hsp20 beneficially attenuate streptozotocin-induced cardiac dysfunction and adverse remodelling. Interestingly, overexpression of Hsp20 also altered the cargo of cardiomyocyte EVs to contain cytoprotective proteins such as phosphorylated-Akt, superoxide dismutase, and survivin.²⁹⁴

7. Preclinical models of diabetic cardiomyopathy

7.1 Animal models

Our understanding of the pathophysiology and identification of therapeutic targets for diabetic cardiomyopathy has relied predominantly on *in vivo* and *in vitro* animal models (Figure 3), in particular, T2DM murine models.^{295,296} In murine models, T2DM can be modelled using a high-fat diet with or without injection of streptozotocin, which is toxic to the β -cells.²⁹⁶ The combination of high-fat diet and streptozotocin allows the animal to mimic the destruction of some β -cell islets, a hallmark of late-stage T2DM.^{296,297} Animals fed with high-fat diet (50–60% kcal fat) often develop cardiac hypertrophy, cardiac fibrosis, and contractile dysfunction. Despite exhibiting many of the cardiac phenotypes similar to patients with diabetic cardiomyopathy, high-fat diet animal models display significant variation in their development of diabetic cardiomyopathy due to a range of food compositions, length of high-fat feeding, and the age of the animal at treatment onset.²⁹⁸

Genetic manipulation has given rise to transgenic small animals that can spontaneously develop hyperglycaemia, insulin resistance, and cardiac abnormalities resembling diabetic cardiomyopathy.²⁹⁶ For example, *ob/ob* and *db/db* mice are based on leptin deficiency or resistance, respectively, and are commonly used for the study of diabetic cardiomyopathy.^{296,299,300} Similarly, there are transgenic rats such as Zucker diabetic fatty rats and Goto-Kakizaki inbred rats.²⁹⁵ Zucker diabetic fatty rats develop T2DM because of a non-functional leptin receptor, whereas Goto-Kakizaki rats spontaneously develop diabetes as a consequence of inbred between Wistar rats which displayed genetic susceptibility to develop high blood glucose.^{162,295,301} However, transgenic animal models can suffer from either too mild or too severe phenotypes, premature death, or highly variable data arising from the underlying mutations, all of which can affect their translatability to the human disease setting.³⁰²




Figure 3 An overview of current preclinical models of Type 2 diabetes. *ob/ob*, leptin deficient mouse (obese); *db/db*, leptin resistant mouse (obese); KK, Kuo-Kondo mouse (obese); KK/A^y, yellow KK mouse (obese); NZO, New Zealand obese mouse (obese); TSOD, Tsumara Suzuki obese diabetes mouse (obese); M16 mouse (obese); ZDF, Zucker diabetic fatty rat; GK, Goto-Kakizaki rat; OLETF, Otsuka Long-Evans Tokushima Fat rat; SHR/N-cp, spontaneously hypertensive rat/NIH-corpulent rat (obese); Cohen, Cohen diabetic rat (non-obese); Torri, Torri rat (non-obese); T2DM, Type 2 diabetes mellitus.

Rodent models are favourable tools to study T2DM and cardiovascular disease due to (i) their short breeding cycle, (ii) ease of genetic manipulation, and (iii) the relatively high degree of genetic homology between mice and humans.²⁹⁶ However, there are fundamental physiological differences between animals and humans. For example, the heart rate of a mouse is ~600 beats per minute, which is in stark contrast to ~60 beats per minute in the human.³⁰³ There are also differences in the cardiac physiology arising from the different machinery in calcium handling, as well as a different expression of contractile protein isoforms and ion channels.³⁰³ Thus, there will inevitably be results obtained from animal models that cannot be translated to humans. For example, dipeptidyl-peptidase 4, a potential therapeutic for diabetic cardiomyopathy, failed to yield positive outcomes in clinical trials despite promising results shown in preclinical animal models.^{5,304,305}

7.2 Human cell-based models of diabetes

Isolated primary adult cardiomyocytes are the closest to native adult human cardiomyocytes in terms of morphology, electrophysiology, metabolism, as well as proteomic and transcriptomic profiles. Primary human cardiovascular cells cultured in hyperglycaemic and hyperlipidaemic conditions to simulate T2DM, or those isolated from T2DM patients, would be the ideal human-specific models to study diabetic cardiomyopathy

and to help streamline the translation of findings that are safe and effective in humans.²⁰⁵ However, studies on primary human cardiomyocytes are lacking in the literature, due to the scarcity of viable human heart tissue, and the technical difficulties in isolating and maintaining primary adult cardiomyocytes.³⁰⁶ These limitations warrant the establishment of alternative pre-clinical human cardiac models for mechanistic studies, as well as for drug discovery, which can be addressed with human PSCs.^{307,308} Human PSCs can self-renew indefinitely, to provide an inexhaustible source of human cells for studying human diseases and drug screening. PSCs can also differentiate into all derivatives of the three germ layers, including *bona fide* cardiovascular cells, which can be cultured for extended periods of time allowing for chronic treatment of test compounds.^{307,309,310} Importantly, unlike primary cardiomyocytes isolated from biopsies that are a snapshot in time, cardiovascular cells derived from PSCs provide an opportunity to examine the early stages of diseases and can be used to study the progressive pathogenic mechanisms of diseases.

There are two main types of PSCs, embryonic stem cells, and iPSCs. Human embryonic stem cells are derived from the undifferentiated inner cell mass of a human embryo at the blastocyst stage and were first isolated in 1998.³¹¹ However, the applications of human embryonic stem cells are often restricted by the ethical concerns surrounding the

destruction of a human embryo, the difficulty in obtaining embryonic stem cells with specific disease phenotypes, and they are usually not genetically matched with patients for transplantation.³⁰⁷ The breakthrough offered by iPSCs has largely overcome these limitations. Following their success in generating the first iPSCs from mouse fibroblasts, Yamanaka and co-workers³¹² established human iPSCs from human fibroblasts through lentivirus-mediated transduction of pluripotency factors OCT3/4, SOX2, KLF4, and c-MYC. Importantly, iPSCs have the same genetic makeup as the donor cells from which they were generated, making them a promising cell source for personalized medicine. Since their discovery, human iPSCs have been widely employed to model different diseases including diabetic cardiomyopathy.³⁰⁷ Significantly, iPSCs generated from different patients with diverse generic backgrounds will capture clinical heterogeneity and enable disease modelling and drug testing at the population level. This idea was made possible through the establishment of HLA haplobanks with clinical-grade iPSC lines from donors covering the worldwide population by several organizations such as the Global Alliance for iPSC Therapies (GAIiT).^{313–315}

Cardiomyocytes derived from human iPSCs have been employed to model diabetic cardiomyopathy^{316–318} (Table 1). Similar to findings in animal models, cardiomyocytes derived from human iPSCs cultured in high glucose conditions exhibit an appropriate disease phenotype such as increased expression of hypertrophic markers and pro-inflammatory factors, accumulation of intracellular lipids, and reduced contractility.^{316–318} Although cardiomyocytes derived from patient iPSCs have conventionally been used to model a variety of hereditary monogenic cardiac disorders,^{327,328} they are increasingly being appreciated for their ability to faithfully capture the cardiac pathophysiology of various non-hereditary lifestyle-related cardiac diseases and cardiac diseases with polygenic risk variants like T2DM.³²⁹ Indeed, cardiomyocytes derived from iPSCs generated from T2DM patients have been shown to recapitulate known cardiomyopathic phenotypes including cellular hypertrophy, impaired contractility, calcium handling abnormalities, metabolic dysregulation, and abnormal TGF- β signalling in the absence of diabetic culture conditions.^{308,316}

7.3 Multicellular human organoid models

Unlike the native heart, 2D cell culture models do not fully recapitulate complex cellular interactions between different cell types under physiological and pathophysiological conditions such as diabetic cardiomyopathy (Figure 4).³⁰⁷ The advent of 3D cell culture systems, such as self-organizing cardiac organoids, has addressed this limitation to some extent. A cardiac organoid is a 3D tissue mimicry that can recreate the native microenvironment and tissue architecture as well as model various pathophysiological processes *in vitro*.^{330–335} In recent years, several studies had established human iPSC-derived cardiac organoids and microtissues consisting of cardiomyocytes and non-myocyte cell populations, mainly fibroblasts and endothelial cells.^{333,336,337} The possibility to derive all cardiac cell types from a single human iPSC source will permit isogenic disease modelling and pave the way for personalized medicine. However, further developments to incorporate other essential non-myocyte cell populations such as autonomic neurons, VSMCs, pericytes, and immune cells are needed to accurately model the cellular heterogeneity of native heart tissue and the tissue response to disease stimuli. Recent studies showing functional co-culture of human iPSC-derived sympathetic neurons and cardiomyocytes in a 2D culture system^{338,339} raise the possibility of establishing an innervated 3D cardiac organoid model. These multi-cell type models of the heart can be

expected to play a huge role in the early stages of drug development where the prediction of cardiac toxicity will be improved, allowing a more efficient transition from preclinical to clinical studies.³³⁰ For example, a model of diabetic vasculopathy was recently described, involving a self-organizing 3D human blood vessel organoid model capable of modelling diabetic vasculopathy when cultured in high glucose media or exposed *in vivo* to a diabetic milieu in mice.³²⁶ The blood vessel organoids generated through directed differentiation of human PSCs consist of networks of CD31⁺ endothelial cells surrounded by pericytes, mesenchymal stem-like cells, and CD45⁺ haematopoietic cells. Using this advanced pre-clinical human 3D model, the authors successfully identified NOTCH3 and its ligand DLL4 as a new potential therapeutic target for diabetic microvasculopathy.³²⁶

Currently, cardiac organoid technology is presented with challenges including insufficient robustness and reliability for mimicking complex multicellular microenvironments, reproducibility of protocols with appropriate quality controls, and the precise ratio of cardiomyocyte and other non-myocytes to achieve a robust model.³³⁰ In addition to the intercellular crosstalk within the heart tissue, inter-organ crosstalk is also regarded as highly relevant to the pathophysiology of systemic diseases like diabetes. In this regard, the development of organ-on-a-chip technologies has allowed studies of crosstalk between organs in disease development and progression.^{340–342} These organ-on-a-chip platforms allow simultaneous culture of multiple bioengineered organoids or microtissues from different organs in a closed circulatory perfusion microfluidic device under a controlled environment of medium flow between different ‘organ’ compartments and local electromechanical properties.^{340–342} The evolution of multi-organ on a chip approaches may provide superior *in vitro* systems to study the dynamic biochemical interactions and responses of cells from different organs in diabetic conditions for drug and therapy development.

8. Therapies for diabetic cardiomyopathy

Treatments for diabetic cardiomyopathy have largely focused on managing the symptoms of diabetes, such as controlling glycaemic control, lowering lipid levels, and managing oxidative stress.⁵ However, glucose-lowering treatments such as insulin sensitizers,³⁴³ glucagon-like peptide (GLP1) agonists,³⁴⁴ sulfonylureas, and some dipeptidyl peptidase-4 inhibitors,³⁴⁵ have had limited clinical success preventing HF and can even increase the risk of HF. Metformin, a first-line treatment for T2DM, has been contraindicated for patients with HF due to the possible risk of lactic acidosis.³⁴⁶ However, recent pre-clinical and clinical data suggest the risk of lactic acidosis may no higher for metformin than for any other anti-hyperglycaemic drug.^{347,348} Most pre-clinical studies have emphasized intra-cardiomyocyte signalling pathways and overlooked the crosstalk between cardiomyocytes and other supporting cells. The interaction between cardiomyocytes and other resident cardiac non-myocytes such as endothelial cells and cardiac fibroblast has gained increasing attention and it is undoubtedly important for maintaining cardiac physiology and driving pathological processes.¹³⁵ For instance, endothelial dysfunction can result in hyperinsulinaemia, glucose intolerance, and insulin resistance in the mouse following the inducible endothelial-specific knockout of bone morphogenetic protein-binding endothelial regulator through its interaction with the cholesterol transporter Niemann-Pick C1.³⁴⁹ This suggests an active endocrine role for the endothelium in regulating glucose homeostasis and a potential basis for cardiovascular disease in T2DM.

Table 1 Modeling diabetic cardiomyopathy and vasculopathy with human PSCs

Cell composition	Simulated diabetes conditions	Phenotypes	References
2D models			
CMs	10 mM glucose, 10 nM endothelin-1, and 1 μ M cortisol for 2 days	<ul style="list-style-type: none"> • Cellular hypertrophy • Increased Troponin I and FABP3 proteins secretion • Loss of sarcomeric integrity • Reduced frequency of calcium transients • Increased frequency of irregular beat rate • Increased intracellular peroxidized lipid 	Drawnel et al. ³¹⁶
CMs	Derived from T2DM patients' iPSCs	<ul style="list-style-type: none"> • Loss of sarcomeric integrity • Reduced frequency of calcium transients • Increased frequency of irregular beat rate • Increased intracellular peroxidized lipid 	Drawnel et al. ³¹⁶
CMs	25 mM glucose for 1 day	<ul style="list-style-type: none"> • Increased superoxide production • Increased mitochondrial membrane potential • Increased mitochondrial fission 	Canfield et al. ³¹⁹
CMs	33 mM glucose	<ul style="list-style-type: none"> • Reduced glycolytic activity and mitochondrial respiration 	Prakoso et al. ³²⁰
CMs	10 mM glucose, 10 μ g/mL insulin, 0.2 mM palmitic acid, 10 nM endothelin-1, and 1 μ M cortisol for 3 days	<ul style="list-style-type: none"> • Increased intracellular lipid droplets and ceramide levels • Increased mitochondrial superoxide levels • Reduced oxygen consumption, mitochondrial β-oxidation and respiratory capacity • Increased mitophagy • Loss of sarcomeric integrity • Reduced beating rate • Increased frequency of irregular calcium transients 	Bekhite et al. ³²¹
CMs	Derived from T2DM patients' iPSCs	<ul style="list-style-type: none"> • Increased intracellular lipid droplets • Cellular hypertrophy • Increased sensitivity to glucolipotoxicity • Reduced mitochondrial membrane potential • Increase ROS • Reduced oxygen consumption and ATP production • Increased frequency of irregular beat rate • Increased frequency of irregular calcium transients 	Tang et al. ³⁰⁸
CMs	10 mM glucose, 10 nM endothelin-1, and 1 μ M cortisol for 3 days	<ul style="list-style-type: none"> • Cellular hypertrophy 	Tang et al. ³⁰⁸
CMs	22 mM glucose for 14 days	<ul style="list-style-type: none"> • Cellular hypertrophy • Reduced contractility • Increased amplitude of calcium transient • Reduced glycolytic capacity 	Ng et al. ³¹⁷
Endothelial cells	Derived from T2DM patients' iPSCs	<ul style="list-style-type: none"> • Reduced angiogenic potential • Reduced NO production • Increased endothelin-1 secretion • Disrupted glycine homeostasis • Reduced growth rates and increased cell senescence • Reduced mitochondrial membrane potential and ATP production 	Su et al. ³²²
Endothelial cells	33 mM glucose and 10 nM endothelin-1 for 3 days	<ul style="list-style-type: none"> • Reduced angiogenic potential • Increased ROS • Reduced ATP levels • Reduced autophagy • Increased mitochondria fragmentation • Increased susceptibility to simulated ischaemia-reperfusion injury 	Ong et al. ³²³

Continued

Table 1 Continued

Cell composition	Simulated diabetes conditions	Phenotypes	References
3D models			
CMs	12 mM glucose for 7 days	<ul style="list-style-type: none">• Impaired self-assemble into compact microtissue with thicker fibres• Shorter duration of calcium transient and larger amplitudes of calcium transient when subjected to electrical stimulation• Increased beating rate	Balistreri et al. ³²⁴
CMs, epicardial cells, endocardial cells, endothelial cells, cardiac fibroblasts.	11.1 mM glucose and 1.14 nM insulin for 2 weeks	<ul style="list-style-type: none">• Increased in organoid size• Higher frequency of irregular action potential• Reduced oxygen consumption and increased glycolysis• Increased lipid droplet• Myocyte structural defects	Lewis-Israeli et al. ³²⁵
Endothelial cells, pericytes	75 mM glucose ± 1 ng/mL TNF and 1 ng/mL IL-6 for 3 weeks	<ul style="list-style-type: none">• Reduced ratio of endothelial cells to pericytes• Increased vascular membrane ECM (collagen type IV, fibronectin, laminin, and perlecan)• Thickening and splitting of the basement membrane layer	Wimmer et al. ³²⁶

CMs, cardiomyocytes; ECM, extracellular matrix.

8.1 SGLT2 inhibitors as promising therapeutics for diabetic cardiomyopathy

Perhaps the most exciting and promising news in diabetic cardiomyopathy and HF more generally, is the recent advent of the SGLT2 inhibitors as a therapy for HFpEF.³⁵⁰ Initially promoted solely as a class of antidiabetic drugs, SGLT2 inhibitors improve glycaemic control, reduce body mass, and lower blood pressure.³⁵¹ However, over several clinical trials, the SGLT2 inhibitors dapagliflozin,³⁵² empagliflozin,³⁵³ canagliflozin,³⁵⁴ and others, were shown to prevent HF and reduce hospitalization and cardiovascular death in T2DM patients with HFpEF. A recent landmark study, the Empagliflozin Outcome Trial in Patients with Chronic HFpEF (EMPEROR-Preserved), showed that empagliflozin reduced the risk of cardiovascular death or hospitalization for HF in both diabetic and non-diabetic patients with HFpEF.³⁵⁰ Significantly, this makes SGLT2 inhibitors the first class of medications to confer benefits across both HFpEF and HFpEF, and a promising therapy for treating diabetic cardiomyopathy.

8.2 The cardioprotective effect of SGLT2 inhibitors

The cardioprotective effects by SGLT2 inhibitors are known to be independent of glycaemic control, or conventional risk factors such as body mass and blood pressure.^{355,356} It has been widely reported that SGLT2 is expressed almost exclusively in the proximal tubular cells of the kidney where it facilitates glucose reabsorption.^{357,358} Numerous hypotheses for how SGLT2 inhibitors confer cardioprotection have been proposed. These include reduced cardiac remodelling, reduced plasma volume, improved diastolic function and Ca²⁺ and Na²⁺ homeostasis, reduced oxidative stress and inflammation, increased metabolism of ketone bodies, and increased autophagy, which have been recently reviewed.³⁵⁹ Undoubtedly, the mechanisms underlying the cardioprotective effect of SGLT2 inhibitors remain unclear, and made more difficult to explain

by the apparent absence of SGLT2 in human heart tissue.³⁶⁰ Interestingly, several lines of evidence point to SGLT2 expression in different vascular cell types including bovine retinal pericytes,¹⁸³ human umbilical vein endothelial cells,³⁶¹ and mouse aorta and aortic endothelial cells.³⁶² While at lower levels than in the kidney, there are reports of SGLT2 expression in aortic VSMCs isolated from human³⁶³ and rat.³⁶⁴ Patient-derived epicardial adipose tissue and stromal vascular cells also express SGLT2, which was shown to promote glucose uptake in response to dapagliflozin.³⁶⁵ These studies suggest another plausible mechanism of SGLT2 inhibitor-mediated cardioprotection via either direct or indirect actions on the cardiac non-myocyte populations and extra-cardiac tissues.

Recent reports document beneficial *in vivo* and *in vitro* effects of SGLT2 inhibitors on VSMC^{363,364} and endothelial function^{362,366–369} in both diabetes and non-diabetes. Endothelial function is improved by SGLT2 inhibitor therapy in patients with either uncontrolled T2DM³⁶⁷ or those with T2DM and chronic HF.³⁶⁸ In mouse and rat models of T2DM, SGLT2 inhibitors have been shown to rescue endothelial function,³⁶² improve impaired endothelium-dependent vasodilation by increasing eNOS activity,³⁶⁹ and reduce neointima formation following vascular injury when used in combination with dipeptidyl peptidase-4.³⁶⁴ In non-diabetic settings, canagliflozin has been shown to preserve the integrity of cellular junctions in human endothelial cells exposed to septic plasma via an α1AMPK-dependent pathway,³⁷⁰ while empagliflozin prevents VSMC transition towards a synthetic phenotype, reducing proliferation and migration following IL-7A induced oxidative stress and inflammation.³⁶³ Endothelial cells can undergo endothelial-to-mesenchymal transition and contribute to fibrosis in diabetic cardiomyopathy.³⁷¹ Both dapagliflozin and metformin have been shown to reduce cardiac fibrosis and endothelial-to-mesenchymal transition in peripheral endothelial cells in a mouse model of T2DM induced by high-fat diet feeding combined with streptozocin treatment.³⁷² Human umbilical vein endothelial cells exposed to hyperglycaemia also




Figure 4 The physiological and human relevance of preclinical disease models. The development of effective therapies for patients is largely impeded by the lack of reliable models with strong biological relevance to human disease. *In vivo* (blue circles) animal models, especially small animal models, have predominantly been employed for their physiological complexity at the expense of biological relevance to the human. Although primary cells from human cardiac tissues represent the most ideal cell type to model human disease, their availability and accessibility are limited. The establishment of 3D cardiac organoids from human PSCs has revolutionized human disease modelling, providing a mimicry of human heart physiology *in vitro* (red circles). Cardiac organoids provide enhanced biological complexity such as a 3D microenvironment allowing interaction between cardiomyocytes and non-myocytes compared with the conventional *in vitro* culture, which is generally monocellular 2D culture.

undergo endothelial-to-mesenchymal transition and induce excessive extracellular collagen deposition, which can be reversed with dapagliflozin through AMPK α -mediated TGF β signalling.³⁷²

SGLT2 inhibitors might also exert cardioprotection by regulating the immune response. Following myocardial infarction, SGLT2 inhibitors increase cardiac M2 macrophage numbers and levels of IL-10, a potent anti-inflammatory cytokine.³⁷³ Serum levels of IL-10 also increase following dapagliflozin treatment in T2DM patients.³⁷⁴ In addition to the immune response, evidence also points to an effect of SGLT2 inhibitors on the autonomic nervous system. T2DM patients treated with SGLT2 inhibitors report a lower incidence of ventricular arrhythmias³⁷⁵ and atrial flutter.³⁷⁶ Traditionally, diuretics-like SGLT2 inhibitors increase sympathetic tone.³⁷⁷ However, treatment with SGLT2 inhibitors does not increase sympathetic tone,³⁷⁸ suggesting that they may act on the sympathetic nervous system to reduce hyperactivity.^{379,380} Indeed, dapagliflozin has been shown to attenuate the increase in cardiac and renal tyrosine hydroxylase positive nerve fibres observed in a mouse model of T2DM induced by high-fat diet.³⁸¹ However, the expression of SGLT2 in human autonomic neurons

remains to be determined. Collectively, these studies highlight the possible effects of SGLT2 inhibitors on the cardiac non-myocytes, plausibly by systemic actions, which could be harnessed as a specific therapy for diabetic cardiomyopathy.

9. Conclusion

The pathogenesis of diabetic cardiomyopathy involves a combination of abnormal extracellular matrix deposition, metabolic perturbations, oxidative stress, and inflammation, which lead to pathogenic cardiac remodelling and dysfunction. While pro-inflammatory cytokines, AGEs and ROS drive maladaptive changes to the cardiomyocytes, the pathogenesis of diabetic cardiomyopathy cannot be explained by these factors alone. Cardiac fibroblasts, the coronary vasculature, the autonomic nervous system, and immune cells regulate electrical, chemical, and biomechanical signalling in the heart, maintain cardiac homeostasis, and in diabetic conditions, contribute to the pathogenesis of diabetic cardiomyopathy. The involvement of non-myocytes in the pathogenesis and pathology of

diabetic cardiomyopathy should not be viewed as an impediment, but rather as an opportunity to leverage our existing models and treatments for the development of new and effective therapeutic strategies.

Authors' contributions

J.G.L. and S.Y.L. conceived the idea for the article; R.J.P., J.G.L., and S.Y.L. performed the literature search and data synthesis; R.J.P. prepared the original draft; R.J.P., J.G.L., S.Y.L., R.H.R., and D.J.H. critically revised the work.

Conflict of interest: none declared.

Funding

This work was supported by grants from the St Vincent's Hospital (Melbourne) Research Endowment Fund, Stafford Fox Medical Research Foundation, St Vincent's Institute Rising Star Award, and infrastructure funding from the Victorian Government (Australia) Operational Infrastructure Support Scheme to St Vincent's Institute of Medical Research. D.J.H. is supported by the Duke-NUS Signature Research Programme funded by the Ministry of Health, Singapore Ministry of Health's National Medical Research Council under its Clinician Scientist-Senior Investigator scheme (NMRC/CSA-SI/0011/2017), Centre Grant (CGAug16M006), and Collaborative Centre Grant scheme (NMRC/CGAug16C006).

Data availability

No new data were generated or analysed in support of this research.

References

- DeFronzo RA, Ferrannini E, Groop L, Henry RR, Herman WH, Holst JJ, Hu FB, Kahn CR, Raz I, Shulman GI, Simonson DC, Testa MA, Weiss R. Type 2 diabetes mellitus. *Nat Rev Dis Primers* 2015;**1**:15019.
- Htay T, Soe K, Lopez-Perez A, Doan AH, Romagosa MA, Aung K. Mortality and cardiovascular disease in type 1 and type 2 diabetes. *Curr Cardiol Rep* 2019;**21**:45.
- Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, Colagiuri S, Guariguata L, Motala AA, Ogurtsova K, Shaw JE, Bright D, Williams R. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition. *Diabetes Res Clin Pract* 2019;**157**:107843.
- DiMeglio LA, Evans-Molina C, Oram RA. Type 1 diabetes. *Lancet* 2018;**391**:2449–2462.
- Tan Y, Zhang Z, Zheng C, Wintergerst KA, Keller BB, Cai L. Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence. *Nat Rev Cardiol* 2020;**17**:585–607.
- Zhu Y, Zhang C. Prevalence of gestational diabetes and risk of progression to type 2 diabetes: a global perspective. *Curr Diab Rep* 2016;**16**:7.
- Esteve E, Ricart W, Fernández-Real JM. Gut microbiota interactions with obesity, insulin resistance and type 2 diabetes: did gut microbiota co-evolve with insulin resistance? *Curr Opin Clin Nutr Metab Care* 2011;**14**:483–490.
- Ikehara S, Iso H, Maruyama K, Ukawa S, Tamakoshi A. Television viewing time, walking time, and risk of type 2 diabetes in Japanese men and women: the Japan collaborative cohort study. *Prev Med* 2019;**118**:220–225.
- Del Bosque-Plata L, Martínez-Martínez E, Espinoza-Camacho M, Gragnoli C. The role of TCF7L2 in type 2 diabetes. *Diabetes* 2021;**70**:1220–1228.
- Grant SF, Thorleifsson G, Reynisdottir I, Benediktsson R, Manolescu A, Sainz J, Helgason A, Stefansson H, Emilsson V, Helgadóttir A, Styrkarsdóttir U, Magnusson KP, Walters GB, Palsdóttir E, Jonsdóttir T, Gudmundsdóttir T, Gylfason A, Saemundsdóttir J, Wilensky RL, Reilly MP, Rader DJ, Bagger Y, Christiansen C, Gudnason V, Sigurdsson G, Thorsteinsdóttir U, Gulcher JR, Kong A, Stefansson K. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. *Nat Genet* 2006;**38**:320–323.
- Wilcox G. Insulin and insulin resistance. *Clin Biochem Rev* 2005;**26**:19–39.
- Yaribeygi H, Farrokhi FR, Butler AE, Sahebkar A. Insulin resistance: review of the underlying molecular mechanisms. *J Cell Physiol* 2019;**234**:8152–8161.
- Aroor AR, Mandavia CH, Sowers JR. Insulin resistance and heart failure: molecular mechanisms. *Heart Fail Clin* 2012;**8**:609–617.
- Abdul-Ghani MA, Tripathy D, DeFronzo RA. Contributions of β -cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. *Diabetes Care* 2006;**29**:1130–1139.
- Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. *Lancet* 2014;**383**:1068–1083.
- Viigimaa M, Sachinidis A, Toumpourleka M, Koutsampasopoulos K, Alliksoo S, Titma T. Macrovascular complications of type 2 diabetes mellitus. *Curr Vasc Pharmacol* 2020;**18**:110–116.
- Gregg EW, Sattar N, Ali MK. The changing face of diabetes complications. *Lancet Diabetes Endocrinol* 2016;**4**:537–547.
- Chawla A, Chawla R, Jaggi S. Microvascular and macrovascular complications in diabetes mellitus: distinct or continuum? *Indian J Endocrinol Metab* 2016;**20**:546–551.
- Avogaro A, Fadini GP. Microvascular complications in diabetes: a growing concern for cardiologists. *Int J Cardiol* 2019;**291**:29–35.
- Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. *Am J Cardiol* 1974;**34**:29–34.
- Pillarsetti S. Potential drug combinations to reduce cardiovascular disease burden in diabetes. *Trends Pharmacol Sci* 2016;**37**:207–219.
- Fox CS, Golden SH, Anderson C, Bray GA, Burke LE, de Boer IH, Deedwania P, Eckel RH, Ershow AG, Fradkin J, Inzucchi SE, Kosiborod M, Nelson RG, Patel MJ, Pignone M, Quinn L, Schauer PR, Selvin E, Vafiadis DK. Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: a scientific statement from the American heart association and the American diabetes association. *Diabetes Care* 2015;**38**:1777–1803.
- Mordi IR, Tee A, Palmer CN, McCrimmon RJ, Doney ASF, Lang CC. Microvascular disease and heart failure with reduced and preserved ejection fraction in type 2 diabetes. *ESC Heart Fail* 2020;**7**:1168–1177.
- Maack C, Lehrke M, Backs J, Heinzel FR, Hulot JS, Marx N, Paulus WJ, Rossignol P, Taegtmeier H, Bauersachs J, Bayes-Genis A, Brutsaert D, Bugger H, Clarke K, Cosentino F, De Keulenaer G, Dei Cas A, González A, Huelsmann M, Iaccarino G, Lunde IG, Lyon AR, Pollesello P, Rena G, Rijsen NP, Rosano G, Staels B, van Laake LW, Wanner C, Farmakis D, Filippatos G, Ruschitzka F, Seferovic P, de Boer RA, Heymans S. Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology. *Eur Heart J* 2018;**39**:4243–4254.
- Mordi IR, Pearson ER, Palmer CNA, Doney ASF, Lang CC. Differential association of genetic risk of coronary artery disease with development of heart failure with reduced versus preserved ejection fraction. *Circulation* 2019;**139**:986–988.
- Gargiulo P, Marsico F, Renga F, Dell'Aversana S, Esposito I, Marciano C, Dellegrottaglie S, Perrone-Filardi P, Paolillo S. The metabolic syndrome in heart failure: insights to specific mechanisms. *Heart Fail Rev* 2020;**25**:1–7.
- Ritchie RH, Abel ED. Basic mechanisms of diabetic heart disease. *Circ Res* 2020;**126**:1501–1525.
- Evangelista I, Nuti R, Picchioni T, Dotta F, Palazzuoli A. Molecular dysfunction and phenotypic derangement in diabetic cardiomyopathy. *Int J Mol Sci* 2019;**20**:3264.
- Seferović PM, Petrie MC, Filippatos GS, Anker SD, Rosano G, Bauersachs J, Paulus WJ, Komajda M, Cosentino F, de Boer RA, Farmakis D, Doehner W, Lambrianou E, Lopatin Y, Piepoli MF, Theodorakis MJ, Wiggers H, Lekakis J, Mebazaa A, Mamas MA, Tschöpe C, Hoes AW, Seferović JP, Logue J, McDonagh T, Riley JP, Milinković I, Polovina M, van Veldhuisen DJ, Lainscak M, Maggioni AP, Ruschitzka F, McMurray JJV. Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. *Eur J Heart Fail* 2018;**20**:853–872.
- Regitz-Zagrosek V, Lehmkuhl E, Weickert MO. Gender differences in the metabolic syndrome and their role for cardiovascular disease. *Clin Res Cardiol* 2006;**95**:136–147.
- Donahue RP, Dorn JM, Stranges S, Swanson M, Hovey K, Trevisan M. Impaired fasting glucose and recurrent cardiovascular disease among survivors of a first acute myocardial infarction: evidence of a sex difference? The Western New York experience. *Nutr Metab Cardiovasc Dis* 2011;**21**:504–511.
- Camperi I, Franconi F, Seghieri G, Meloni M. Sex-gender-related therapeutic approaches for cardiovascular complications associated with diabetes. *Pharmacol Res* 2017;**119**:195–207.
- Göbl CS, Brannath W, Bozkurt L, Handisurya A, Anderwald C, Luger A, Krebs M, Kautzky-Willer A, Bischof MG. Sex-specific differences in glycemic control and cardiovascular risk factors in older patients with insulin-treated type 2 diabetes mellitus. *Genet Med* 2010;**7**:593–599.
- Beale AL, Nanayakkara S, Segan L, Mariani JA, Maeder MT, van Empel V, Vizi D, Evans S, Lam CSP, Kaye DM. Sex differences in heart failure with preserved ejection fraction pathophysiology: a detailed invasive hemodynamic and echocardiographic analysis. *JACC Heart Fail* 2019;**7**:239–249.
- Succurro E, Miceli S, Fiorentino TV, Sciacqua A, Perticone M, Andreozzi F, Sesti G. Sex-specific differences in left ventricular mass and myocardial energetic efficiency in non-diabetic, pre-diabetic and newly diagnosed type 2 diabetic subjects. *Cardiovasc Diabetol* 2021;**20**:60.
- Chandramouli C, Reichelt ME, Curl CL, Varma U, Bienvenu LA, Koutsifeli P, Raaijmakers AJA, De Blasio MJ, Qin CX, Jenkins AJ, Ritchie RH, Mellor KM, Delbridge LMD. Diastolic dysfunction is more apparent in STZ-induced diabetic female mice, despite less pronounced hyperglycemia. *Sci Rep* 2018;**8**:2346.
- Fourny N, Beauloye C, Bernard M, Horman S, Desrois M, Bertrand L. Sex differences of the diabetic heart. *Front Physiol* 2021;**12**:661297.

38. Göbl CS, Bozkurt L, Yarragudi R, Prikoszovich T, Tura A, Pacini G, Koppensteiner R, Kautzky-Willer A. Biomarkers of endothelial dysfunction in relation to impaired carbohydrate metabolism following pregnancy with gestational diabetes mellitus. *Cardiovasc Diabetol* 2014;**13**:138.
39. Lee SJ, Lee DW, Kim KS, Lee IK. Effect of estrogen on endothelial dysfunction in postmenopausal women with diabetes. *Diabetes Res Clin Pract* 2001;**54**(Suppl. 2):S81–S92.
40. Marra G, Cotroneo P, Pitocco D, Manto A, Di Leo MA, Ruotolo V, Caputo S, Giardina B, Ghirlanda G, Santini SA. Early increase of oxidative stress and reduced antioxidant defenses in patients with uncomplicated type 1 diabetes: a case for gender difference. *Diabetes Care* 2002;**25**:370–375.
41. Steinberg HO, Paradisi G, Cronin J, Crowde K, Hempfling A, Hook G, Baron AD. Type II diabetes abrogates sex differences in endothelial function in premenopausal women. *Circulation* 2000;**101**:2040–2046.
42. Tang X, Jiang S, Zhang J, Zhou S, Zheng Y. Sex differences in progression of diabetic cardiomyopathy in OVE26 type 1 diabetic mice. *Oxid Med Cell Longev* 2020;**2020**:6961348.
43. Larsen TD, Sabey KH, Knutson AJ, Gandy TCT, Louwagie EJ, Lauterboeck L, Mdaki KS, Baack ML. Diabetic pregnancy and maternal high-fat diet impair mitochondrial dynamics in the developing fetal rat heart by sex-specific mechanisms. *Int J Mol Sci* 2019;**20**:3090.
44. Borghetti G, von Lewinski D, Eaton DM, Sourij H, Houser SR, Wallner M. Diabetic cardiomyopathy: current and future therapies. Beyond glycemic control. *Front Physiol* 2018;**9**:1514.
45. Kim JA, Choi KM. Newly discovered adipokines: pathophysiological link between obesity and cardiometabolic disorders. *Front Physiol* 2020;**11**:568800.
46. Chait A, den Hartigh LJ. Adipose tissue distribution, inflammation and its metabolic consequences, including diabetes and cardiovascular disease. *Front Cardiovasc Med* 2020;**7**:22.
47. Kim EH, Kim HK, Lee MJ, Bae SJ, Choe J, Jung CH, Kim CH, Park JY, Lee WJ. Sex differences of visceral fat area and visceral-to-subcutaneous fat ratio for the risk of incident type 2 diabetes mellitus. *Diabetes Metab J* 2021.
48. Chen X, Mao Y, Hu J, Han S, Gong L, Luo T, Yang S, Qing H, Wang Y, Du Z, Mei M, Zheng L, Lv X, Tang Y, Zhao Q, Zhou Y, He JC, Li Q, Wang Z. Perirenal fat thickness is significantly associated with the risk for development of chronic kidney disease in patients with diabetes. *Diabetes* 2021;**70**:2322–2332.
49. Uygur B, Çelik Ö, Demir AR, Karakayali M, Arslan Ç, Otcu Temur H, Alis D, Yıldırım C, Çörekoğlu B, Ertürk M. Epicardial adipose tissue volume predicts long term major adverse cardiovascular events in patients with Type 2 diabetes. *Türk Kardiyol Dern Ars* 2021;**49**:127–134.
50. Phruksotsai S, Pinyopornpanish K, Euathrongchit J, Leerapun A, Phrommintikul A, Buranapin S, Chattipakorn N, Thongsawat S. The effects of dapagliflozin on hepatic and visceral fat in type 2 diabetes patients with non-alcoholic fatty liver disease. *J Gastroenterol Hepatol* 2021;**36**:2952–2959.
51. Ayton SL, Gulsin GS, McCann GP, Moss AJ. Epicardial adipose tissue in obesity-related cardiac dysfunction. *Heart* 2022;**108**:339–344.
52. Kim J, Joo S, Eom GH, Lee SH, Lee MA, Lee M, Kim KW, Kim DH, Kook H, Kwak TH, Park WJ. CCN5 knockout mice exhibit lipotoxic cardiomyopathy with mild obesity and diabetes. *PLoS One* 2018;**13**:e0207228.
53. Zhou HM, Ti Y, Wang H, Shang YY, Liu YP, Ni XN, Wang D, Wang ZH, Zhang W, Zhong M. Cell death-inducing DFFA-like effector C/CIDEF gene silencing alleviates diabetic cardiomyopathy via upregulating AMPKa phosphorylation. *FASEB J* 2021;**35**:e21504.
54. Huang R, Shi Z, Chen L, Zhang Y, Li J, An Y. Rutin alleviates diabetic cardiomyopathy and improves cardiac function in diabetic ApoEknockout mice. *Eur J Pharmacol* 2017;**814**:151–160.
55. Marfella R, Amarelli C, Cacciatori F, Balestrieri ML, Mansueto G, D'Onofrio N, Esposito S, Mattucci I, Salerno G, De Feo M, D'Amico M, Golino P, Maiello C, Paolisso G, Napoli C. Lipid accumulation in hearts transplanted from nondiabetic donors to diabetic recipients. *J Am Coll Cardiol* 2020;**75**:1249–1262.
56. Olivey HE, Svensson EC. Epicardial-myocardial signaling directing coronary vasculogenesis. *Circ Res* 2010;**106**:818–832.
57. Si Y, Cui Z, Liu J, Ding Z, Han C, Wang R, Liu T, Sun L. Pericardial adipose tissue is an independent risk factor of coronary artery disease and is associated with risk factors of coronary artery disease. *J Int Med Res* 2020;**48**:300060520926737.
58. Yu W, Liu B, Zhang F, Wang J, Shao X, Yang X, Shi Y, Wang B, Xu Y, Wang Y. Association of epicardial fat volume with increased risk of obstructive coronary artery disease in Chinese patients with suspected coronary artery disease. *J Am Heart Assoc* 2021;**10**:e018080.
59. Christensen RH, von Scholten BJ, Hansen CS, Jensen MT, Vilsbøll T, Rossing P, Jørgensen PG. Epicardial adipose tissue predicts incident cardiovascular disease and mortality in patients with type 2 diabetes. *Cardiovasc Diabetol* 2019;**18**:114.
60. Sugita Y, Ito K, Sakurai S, Sakai S, Kuno S. Epicardial adipose tissue is tightly associated with exercise intolerance in patients with type 2 diabetes mellitus with asymptomatic left ventricular structural and functional abnormalities. *J Diabetes Complicat* 2020;**34**:107552.
61. Christensen RH, Hansen CS, von Scholten BJ, Jensen MT, Pedersen BK, Schnohr P, Vilsbøll T, Rossing P, Jørgensen PG. Epicardial and pericardial adipose tissues are associated with reduced diastolic and systolic function in type 2 diabetes. *Diabetes Obes Metab* 2019;**21**:2006–2011.
62. Gruzdeva O, Borodkina D, Uchasova E, Dyleva Y, Barbarash O. Localization of fat deposits and cardiovascular risk. *Lipids Health Dis* 2018;**17**:218.
63. Venuraju SM, Lahiri A, Jeevarethinam A, Rakshit RD, Shah PK, Nilsson J. Association of epicardial fat volume with the extent of coronary atherosclerosis and cardiovascular adverse events in asymptomatic patients with diabetes. *Angiology* 2021;**72**:442–450.
64. Ballasy NN, Jadli AS, Edalat P, Kang S, Fatehi Hassanabad A, Gomes KP, Fedak PWM, Patel VB. Potential role of epicardial adipose tissue in coronary artery endothelial cell dysfunction in type 2 diabetes. *FASEB J* 2021;**35**:e21878.
65. Park J, Kim G, Kim H, Lee J, Lee YB, Jin SM, Hur KY, Kim JH. The association of hepatic steatosis and fibrosis with heart failure and mortality. *Cardiovasc Diabetol* 2021;**20**:197.
66. Roh JH, Park JH, Lee H, Yoon YH, Kim M, Kim YG, Park GM, Lee JH, Seong IW. Higher fatty liver index is associated with increased risk of new onset heart failure in healthy adults: a nationwide population-based study in Korea. *BMC Cardiovasc Disord* 2020;**20**:204.
67. Chung GE, Cho EJ, Yoo JJ, Chang Y, Cho Y, Park SH, Han K, Jeong SM, Yoon KW, Shin DW, Yu SJ, Kim YJ, Yoon JH. Young adults with nonalcoholic fatty liver disease, defined using the fatty liver index, can be at increased risk of myocardial infarction or stroke. *Diabetes Obes Metab* 2022;**24**:465–472.
68. El Hadi H, Di Vincenzo A, Vettor R, Rossato M. Relationship between heart disease and liver disease: a two-way street. *Cells* 2020;**9**:567.
69. Barb D, Bril F, Kalavalapalli S, Cusi K. Plasma fibroblast growth factor 21 is associated with severity of nonalcoholic steatohepatitis in patients with obesity and type 2 diabetes. *J Clin Endocrinol Metab* 2019;**104**:3327–3336.
70. Gao RY, Hsu BG, Wu DA, Hou JS, Chen MC. Serum fibroblast growth factor 21 levels are positively associated with metabolic syndrome in patients with type 2 diabetes. *Int J Endocrinol* 2019;**2019**:5163245.
71. Birukov A, Polemiti E, Jäger S, Stefan N, Schulze MB. Fetuin-A and risk of diabetes-related vascular complications: a prospective study. *Cardiovasc Diabetol* 2022;**21**:6.
72. Shimizu W, Kubota Y, Hoshika Y, Mozawa K, Tara S, Tokita Y, Yodogawa K, Iwasaki YK, Yamamoto T, Takano H, Tsukada Y, Asai K, Miyamoto M, Miyauchi Y, Kodani E, Ishikawa M, Maruyama M, Ogano M, Tanabe J. Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial. *Cardiovasc Diabetol* 2020;**19**:148.
73. Targher G, Mantovani A, Grandi C, Foco L, Motta B, Byrne CD, Pramstaller PP, Tilg H. Association between non-alcoholic fatty liver disease and impaired cardiac sympathetic/parasympathetic balance in subjects with and without type 2 diabetes—the Cooperative Health Research in South Tyrol (CHRIS)-NAFLD sub-study. *Nutr Metab Cardiovasc Dis* 2021;**31**:3464–3473.
74. Laurita KR, Khan S, McMahon T, Dennis AT, Li V, Gaivin R, Sapa H, Fu JD, Schelling JR. Ventricular arrhythmias in mouse models of diabetic kidney disease. *Sci Rep* 2021;**11**:20570.
75. Bolin LP, Saul AD, Bethune Scroggs LL, Horne C. A pilot study investigating the relationship between heart rate variability and blood pressure in young adults at risk for cardiovascular disease. *Clin Hypertens* 2022;**28**:2.
76. Jungen C, Scherschel K, Flenner F, Jee H, Rajendran P, De Jong KA, Nikolaev V, Meyer C, Ardell JL, Tompkins JD. Increased arrhythmia susceptibility in type 2 diabetic mice related to dysregulation of ventricular sympathetic innervation. *Am J Physiol Heart Circ Physiol* 2019;**317**:H1328–H1341.
77. Abdul-Ghani MA, DeFronzo RA. Pathogenesis of insulin resistance in skeletal muscle. *J Biomed Biotechnol* 2010;**2010**:476279.
78. Szaroszyk M, Kattih B, Martin-Garrido A, Trogisch FA, Ditttrich GM, Grund A, Abouissa A, Derlin K, Meier M, Holler T, Korf-Klingebiel M, Völker K, Garfias Macedo T, Pablo Tortola C, Boschmann M, Huang N, Froese N, Zwadlo C, Malek Mohammadi M, Luo X, Wagner M, Cordero J, Geffers R, Batkai S, Thum T, Bork N, Nikolaev VO, Müller OJ, Katus HA, El-Armouche A, Kraft T, Springer J, Dobrev G, Wollert KC, Fiebert J, von Haehling S, Kuhn M, Bauersachs J, Heineke J. Skeletal muscle derived Myoclin protects the heart during pathological overload. *Nat Commun* 2022;**13**:149.
79. Eckardt K, Görgens SV, Raschke S, Eckel J. Myokines in insulin resistance and type 2 diabetes. *Diabetologia* 2014;**57**:1087–1099.
80. Zakharova AN, Kironenko TA, Milovanova KG, Orlova AA, Dyakova EY, Kalinnikova Yu G, Kabachkova AV, Chibalin AV, Kapilevich LV. Treadmill training effect on the myokines content in skeletal muscles of mice with a metabolic disorder model. *Front Physiol* 2021;**12**:709039.
81. Javid HMA, Sahar NE, ZhuGe DL, Huh JY. Exercise inhibits NLRP3 inflammasome activation in obese mice via the anti-inflammatory effect of meteorin-like. *Cells* 2021;**10**:3480.
82. Feraco A, Gorini S, Armani A, Camajani E, Rizzo M, Caprio M. Exploring the role of skeletal muscle in insulin resistance: lessons from cultured cells to animal models. *Int J Mol Sci* 2021;**22**:9327.
83. Zhang X, Hu C, Yuan XP, Yuan YP, Song P, Kong CY, Teng T, Hu M, Xu SC, Ma ZG, Tang QZ. Osteocrin, a novel myokine, prevents diabetic cardiomyopathy via restoring proteasomal activity. *Cell Death Dis* 2021;**12**:624.
84. Ho MY, Wang CY. Role of irisin in myocardial infarction, heart failure, and cardiac hypertrophy. *Cells* 2021;**10**:2103.
85. Xiang L, Xiang G, Yue L, Zhang J, Zhao L. Circulating irisin levels are positively associated with endothelium-dependent vasodilation in newly diagnosed type 2 diabetic patients without clinical angiopathy. *Atherosclerosis* 2014;**235**:328–333.

86. Lin C, Guo Y, Xia Y, Li C, Xu X, Qi T, Zhang F, Fan M, Hu G, Zhao H, Zhao H, Liu R, Gao E, Yan W, Tao L. FNDC5/Irisin attenuates diabetic cardiomyopathy in a type 2 diabetes mouse model by activation of integrin $\alpha V/\beta 5$ -AKT signaling and reduction of oxidative/nitrosative stress. *J Mol Cell Cardiol* 2019;**160**:27–41.
87. Deng J, Zhang N, Chen F, Yang C, Ning H, Xiao C, Sun K, Liu Y, Yang M, Hu T, Zhang Z, Jiang W. Irisin ameliorates high glucose-induced cardiomyocytes injury via AMPK/mTOR signal pathway. *Cell Biol Int* 2020;**44**:2315–2325.
88. Tarquini R, Pala L, Brancati S, Vannini G, De Cosmo S, Mazzocchi G, Rotella CM. Clinical approach to diabetic cardiomyopathy: a review of human studies. *Curr Med Chem* 2018;**25**:1510–1524.
89. Shimizu M, Umeda K, Sugihara N, Yoshio H, Ino H, Takeda R, Okada Y, Nakanishi I. Collagen remodelling in myocardia of patients with diabetes. *J Clin Pathol* 1993;**46**:32–36.
90. Marwick TH, Ritchie R, Shaw JE, Kaye D. Implications of underlying mechanisms for the recognition and management of diabetic cardiomyopathy. *J Am Coll Cardiol* 2018;**71**:339–351.
91. Tang M, Zhang W, Lin H, Jiang H, Dai H, Zhang Y. High glucose promotes the production of collagen types I and III by cardiac fibroblasts through a pathway dependent on extracellular-signal-regulated kinase 1/2. *Mol Cell Biochem* 2007;**301**:109–114.
92. Horn MA. Cardiac physiology of aging: extracellular considerations. *Compr Physiol* 2015;**5**:1069–1121.
93. Aronson D. Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes. *J Hypertens* 2003;**21**:3–12.
94. Souders CA, Bowers SL, Baudino TA. Cardiac fibroblast: the renaissance cell. *Circ Res* 2009;**105**:1164–1176.
95. Russo I, Frangogiannis NG. Diabetes-associated cardiac fibrosis: cellular effectors, molecular mechanisms and therapeutic opportunities. *J Mol Cell Cardiol* 2016;**90**:84–93.
96. Wong TC, Piehler KM, Kang IA, Kadakkal A, Kellman P, Schwartzman DS, Muluksela SR, Simon MA, Shroff SG, Kuller LH, Schelbert EB. Myocardial extracellular volume fraction quantified by cardiovascular magnetic resonance is increased in diabetes and associated with mortality and incident heart failure admission. *Eur Heart J* 2014;**35**:657–664.
97. Wang Z, Ying Z, Bosy-Westphal A, Zhang J, Heller M, Later W, Heymsfield SB, Müller MJ. Evaluation of specific metabolic rates of major organs and tissues: comparison between men and women. *Am J Hum Biol* 2011;**23**:333–338.
98. Bertrand L, Horman S, Beauloye C, Vanoverschelde JL. Insulin signalling in the heart. *Cardiovasc Res* 2008;**79**:238–248.
99. Zamora M, Villena JA. Contribution of impaired insulin signaling to the pathogenesis of diabetic cardiomyopathy. *Int J Mol Sci* 2019;**20**:2833.
100. Salvatore T, Pafundi PC, Galiero R, Albanese G, Di Martino A, Caturano A, Vetrano E, Rinaldi L, Sasso FC. The diabetic cardiomyopathy: the contributing pathophysiological mechanisms. *Front Med (Lausanne)* 2021;**8**:695792.
101. Levelt E, Gulsin G, Neubauer S, McCann GP. Mechanisms in endocrinology: diabetic cardiomyopathy: pathophysiology and potential metabolic interventions state of the art review. *Eur J Endocrinol* 2018;**178**:R127–R139.
102. Mizuno Y, Harada E, Nakagawa H, Morikawa Y, Shono M, Kugimiya F, Yoshimura M, Yasue H. The diabetic heart utilizes ketone bodies as an energy source. *Metabolism* 2017;**77**:65–72.
103. Abdurrahim D, Teo XQ, Woo CC, Chan WX, Lalic J, Lam CSP, Lee PTH. Empagliflozin reduces myocardial ketone utilization while preserving glucose utilization in diabetic hypertensive heart disease: a hyperpolarized ^{13}C magnetic resonance spectroscopy study. *Diabetes Obes Metab* 2019;**21**:357–365.
104. Brahma MK, Ha CM, Pepin ME, Mia S, Sun Z, Chatham JC, Habegger KM, Abel ED, Paterson AJ, Young ME, Wende AR. Increased glucose availability attenuates myocardial ketone body utilization. *J Am Heart Assoc* 2020;**9**:e013039.
105. Chiasson JL, Aris-jilwan N, Bélanger R, Bertrand S, Beauregard H, Ekoé JM, Fournier H, Havrankova J. Diagnosis and treatment of diabetic ketoacidosis and the hyperglycemic hyperosmolar state. *CMAJ* 2003;**168**:859–866.
106. Gollmer J, Zirikli A, Bugger H. Mitochondrial mechanisms in diabetic cardiomyopathy. *Diabetes Metab J* 2020;**44**:33–53.
107. Adeghate E, Singh J. Structural changes in the myocardium during diabetes-induced cardiomyopathy. *Heart Fail Rev* 2014;**19**:15–23.
108. Woldegiorgis G, Yousufzai SY, Shrago E. Studies on the interaction of palmitoyl coenzyme A with the adenine nucleotide translocase. *J Biol Chem* 1982;**257**:14783–14787.
109. Shrago E, Woldegiorgis G, Ruoho AE, DiRusso CC. Fatty acyl CoA esters as regulators of cell metabolism. *Prostaglandins Leukot Essent Fatty Acids* 1995;**52**:163–166.
110. Lopuschuk GD, Ussher JR, Folmes CD, Jaswal JS, Stanley WC. Myocardial fatty acid metabolism in health and disease. *Physiol Rev* 2010;**90**:207–258.
111. Gollmer J, Zirikli A, Bugger H. Established and emerging mechanisms of diabetic cardiomyopathy. *J Lipid Atheroscler* 2019;**8**:26–47.
112. Drosatos K, Schulze PC. Cardiac lipotoxicity: molecular pathways and therapeutic implications. *Curr Heart Fail Rep* 2013;**10**:109–121.
113. Faria A, Persaud SJ. Cardiac oxidative stress in diabetes: mechanisms and therapeutic potential. *Pharmacol Ther* 2017;**172**:50–62.
114. Huynh K, Bernardo BC, McMullen JR, Ritchie RH. Diabetic cardiomyopathy: mechanisms and new treatment strategies targeting antioxidant signaling pathways. *Pharmacol Ther* 2014;**142**:375–415.
115. Qian P, Tian H, Wang Y, Lu W, Li Y, Ma T, Gao X, Yao W. A novel oral glucagon-like peptide 1 receptor agonist protects against diabetic cardiomyopathy via alleviating cardiac lipotoxicity induced mitochondria dysfunction. *Biochem Pharmacol* 2020;**182**:114209.
116. Zhang Z, Wang S, Zhou S, Yan X, Wang Y, Chen J, Mellen N, Kong M, Gu J, Tan Y, Zheng Y, Cai L. Sulforaphane prevents the development of cardiomyopathy in type 2 diabetic mice probably by reversing oxidative stress-induced inhibition of LKB1/AMPK pathway. *J Mol Cell Cardiol* 2014;**77**:42–52.
117. Evans JL, Goldfine ID, Maddux BA, Grodzky GM. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. *Endocr Rev* 2002;**23**:599–622.
118. Yang YC, Tsai CY, Chen CL, Kuo CH, Hou CW, Cheng SY, Aneja R, Huang CY, Kuo WW. Pkc δ activation is involved in ROS-mediated mitochondrial dysfunction and apoptosis in cardiomyocytes exposed to advanced glycation end products (ages). *Aging Dis* 2018;**9**:647–663.
119. Knapp M, Tu X, Wu R. Vascular endothelial dysfunction, a major mediator in diabetic cardiomyopathy. *Acta Pharmacol Sin* 2019;**40**:1–8.
120. Ni R, Cao T, Xiong S, Ma J, Fan GC, Laceyfield JC, Lu Y, Le Tissier S, Peng T. Therapeutic inhibition of mitochondrial reactive oxygen species with mito-TEMPO reduces diabetic cardiomyopathy. *Free Radic Biol Med* 2016;**90**:12–23.
121. Sharma A, Tate M, Mathew G, Vince JE, Ritchie RH, de Haan JB. Oxidative stress and NLRP3-inflammasome activity as significant drivers of diabetic cardiovascular complications: therapeutic implications. *Front Physiol* 2018;**9**:114.
122. Luo B, Li B, Wang W, Liu X, Xia Y, Zhang C, Zhang M, Zhang Y, An F, Bauer PM. NLRP3 gene silencing ameliorates diabetic cardiomyopathy in a type 2 diabetes rat model. *PLoS One* 2014;**9**:e104771.
123. Pavillard LE, Cañadas-Lozano D, Alcocer-Gómez E, Marín-Aguilar F, Pereira S, Robertson AAB, Muntané J, Ryffel B, Cooper MA, Quiles JL, Bullón P, Ruiz-Cabello J, Cordero MD. NLRP3-inflammasome inhibition prevents high fat and high sugar diets-induced heart damage through autophagy induction. *Oncotarget* 2017;**8**:99740–99756.
124. Wang B, Chandrasekera PC, Pippin JJ. Leptin- and leptin receptor-deficient rodent models: relevance for human type 2 diabetes. *Curr Diabetes Rev* 2014;**10**:131–145.
125. Kayama Y, Minamino T, Toko H, Sakamoto M, Shimizu I, Takahashi H, Okada S, Tateno K, Moriya J, Yokoyama M, Nojima A, Yoshimura M, Egashira K, Aburatani H, Komuro I. Cardiac 12/15 lipoxygenase-induced inflammation is involved in heart failure. *J Exp Med* 2009;**206**:1565–1574.
126. Palomer X, Salvadó L, Barroso E, Vázquez-Carrera M. An overview of the crosstalk between inflammatory processes and metabolic dysregulation during diabetic cardiomyopathy. *Int J Cardiol* 2013;**168**:3160–3172.
127. Zhao MX, Zhou B, Ling L, Xiong XQ, Zhang F, Chen Q, Li YH, Kang YM, Zhu GQ. Salusin- β contributes to oxidative stress and inflammation in diabetic cardiomyopathy. *Cell Death Dis* 2017;**8**:e2690.
128. Tian CJ, Zhang JH, Liu J, Ma Z, Zhen Z. Ryanodine receptor and immune-related molecules in diabetic cardiomyopathy. *ESC Heart Fail* 2021;**8**:2637–2646.
129. Jia G, Whaley-Connell A, Sowers JR. Diabetic cardiomyopathy: a hyperglycaemia- and insulin-resistance-induced heart disease. *Diabetologia* 2018;**61**:21–28.
130. Perbellini F, Watson SA, Bardi I, Terracciano CM. Heterocellularity and cellular crosstalk in the cardiovascular system. *Front Cardiovasc Med* 2018;**5**:143.
131. Yu Y, Hu L, Xu Y, Wu S, Chen Y, Zou W, Zhang M, Wang Y, Gu Y. Impact of blood glucose control on sympathetic and vagus nerve functional status in patients with type 2 diabetes mellitus. *Acta Diabetol* 2020;**57**:141–150.
132. Adameova A, Dhalla NS. Role of microangiopathy in diabetic cardiomyopathy. *Heart Fail Rev* 2014;**19**:25–33.
133. Pinto AR, Ilynykh A, Ivey MJ, Kuwabara JT, D'Antoni ML, Debuque R, Chandran A, Wang L, Arora K, Rosenthal NA, Talquist MD. Revisiting cardiac cellular composition. *Circ Res* 2016;**118**:400–409.
134. Levick SP, Widiapradja A. The diabetic cardiac fibroblast: mechanisms underlying phenotype and function. *Int J Mol Sci* 2020;**21**:970.
135. Cohen CD, De Blasio MJ, Lee MKS, Farrugia GE, Prakoso D, Krstevski C, Deo M, Donner DG, Kiriazis H, Flynn MC, Gaynor TL, Murphy AJ, Drummond GR, Pinto AR, Ritchie RH. Diastolic dysfunction in a pre-clinical model of diabetes is associated with changes in the cardiac non-myocyte cellular composition. *Cardiovasc Diabetol* 2021;**20**:116.
136. Frangogiannis NG. The extracellular matrix in ischemic and nonischemic heart failure. *Circ Res* 2019;**125**:117–146.
137. Hutchinson KR, Lord CK, West TA, Stewart JA Jr, Gupta S. Cardiac fibroblast-dependent extracellular matrix accumulation is associated with diastolic stiffness in type 2 diabetes. *PLoS One* 2013;**8**:e72080.
138. Asbun J, Manso AM, Villarreal FJ. Profibrotic influence of high glucose concentration on cardiac fibroblast functions: effects of losartan and vitamin E. *Am J Physiol Heart Circ Physiol* 2005;**288**:H227–H234.
139. Zhou Y, Pocatzek MH, Berecek KH, Murphy-Ullrich JE. Thrombospondin 1 mediates angiotensin II induction of TGF- β activation by cardiac and renal cells under both high and low glucose conditions. *Biochem Biophys Res Commun* 2006;**339**:633–641.
140. Singh VP, Baker KM, Kumar R. Activation of the intracellular renin-angiotensin system in cardiac fibroblasts by high glucose: role in extracellular matrix production. *Am J Physiol Heart Circ Physiol* 2008;**294**:H1675–H1684.
141. Aguilar H, Frickovsky E, Ihm S, Schimke M, Maya-Ramos L, Aroonsakool N, Ceballos G, Dillmann W, Villarreal F, Ramirez-Sanchez I. Role for high-glucose-induced protein

- O-GlcNAcylation in stimulating cardiac fibroblast collagen synthesis. *Am J Physiol Cell Physiol* 2014;**306**:C794–C804.
142. Zhang X, Stewart JA Jr, Kane ID, Massey EP, Cashatt DO, Carver WE. Effects of elevated glucose levels on interactions of cardiac fibroblasts with the extracellular matrix. *In Vitro Cell Dev Biol Anim* 2007;**43**:297–305.
 143. Shamhart PE, Luther DJ, Adapala RK, Bryant JE, Petersen KA, Meszaros JG, Thodeti CK. Hyperglycemia enhances function and differentiation of adult rat cardiac fibroblasts. *Can J Physiol Pharmacol* 2014;**92**:598–604.
 144. Kai H, Mori T, Tokuda K, Takayama N, Tahara N, Takemiya K, Kudo H, Sugi Y, Fukui D, Yasukawa H, Kuwahara F, Imaizumi T. Pressure overload-induced transient oxidative stress mediates perivascular inflammation and cardiac fibrosis through angiotensin II. *Hypertens Res* 2006;**29**:711–718.
 145. Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. *J Am Coll Cardiol* 2013;**62**:263–271.
 146. Chilton L, Ohya S, Freed D, George E, Drohic V, Shibukawa Y, Maccannell KA, Imaizumi Y, Clark RB, Dixon IM, Giles WR. K⁺ currents regulate the resting membrane potential, proliferation, and contractile responses in ventricular fibroblasts and myofibroblasts. *Am J Physiol Heart Circ Physiol* 2005;**288**:H2931–H2939.
 147. Walsh KB, Zhang J. Neonatal rat cardiac fibroblasts express three types of voltage-gated K⁺ channels: regulation of a transient outward current by protein kinase C. *Am J Physiol Heart Circ Physiol* 2008;**294**:H1010–H1017.
 148. Chu M, Novak SM, Cover C, Wang AA, Chinyere IR, Juneman EB, Zarnescu DC, Wong PK, Gregorio CC. Increased cardiac arrhythmogenesis associated with gap junction remodeling with upregulation of RNA-binding protein FXR1. *Circulation* 2018;**137**:605–618.
 149. Kho C, Lee A, Hajjar RJ. Altered sarcoplasmic reticulum calcium cycling—targets for heart failure therapy. *Nat Rev Cardiol* 2012;**9**:717–733.
 150. Chen F, Zhao WT, Chen FX, Fu GS, Mou Y, Hu SJ. High glucose promotes gap junctional communication in cultured neonatal cardiac fibroblasts via AMPK activation. *Mol Biol (Mosk)* 2014;**48**:599–606.
 151. Rychli K, Kaun C, Hohensinner PJ, Dorfner AJ, Pfaffenberger S, Niessner A, Bauer M, Dietl W, Podesser BK, Maurer G, Huber K, Wojta J. The anti-angiogenic factor PEDF is present in the human heart and is regulated by anoxia in cardiac myocytes and fibroblasts. *J Cell Mol Med* 2010;**14**:198–205.
 152. Ubil E, Duan J, Pillai IC, Rosa-Garrido M, Wu Y, Bargiacchi F, Lu Y, Stanboul S, Huang J, Rojas M, Vondriska TM, Stefani E, Deb A. Mesenchymal-endothelial transition contributes to cardiac neovascularization. *Nature* 2014;**514**:585–590.
 153. Humeres C, Frangogiannis NG. Fibroblasts in the infarcted, remodeling, and failing heart. *JACC Basic Transl Sci* 2019;**4**:449–467.
 154. Altara R, Mallat Z, Booz GW, Zouein FA. The CXCL10/CXCR3 axis and cardiac inflammation: implications for immunotherapy to treat infectious and noninfectious diseases of the heart. *J Immunol Res* 2016;**2016**:4396368.
 155. Hu J, Wang S, Xiong Z, Cheng Z, Yang Z, Lin J, Wang T, Feng X, Gao E, Wang H, Sun D. Exosomal Mst1 transfer from cardiac microvascular endothelial cells to cardiomyocytes deteriorates diabetic cardiomyopathy. *Biochim Biophys Acta Mol Basis Dis* 2018;**1864**:3639–3649.
 156. Wan A, Rodrigues B. Endothelial cell-cardiomyocyte crosstalk in diabetic cardiomyopathy. *Cardiovasc Res* 2016;**111**:172–183.
 157. Goveia J, Sapor P, Carmeliet P. Principles of targeting endothelial cell metabolism to treat angiogenesis and endothelial cell dysfunction in disease. *EMBO Mol Med* 2014;**6**:1105–1120.
 158. Popov D. Endothelial cell dysfunction in hyperglycemia: phenotypic change, intracellular signaling modification, ultrastructural alteration, and potential clinical outcomes. *Int J Diabetes Mellit* 2010;**2**:189–195.
 159. Marciano C, Galderisi M, Gargiulo P, Acampa W, D'Amore C, Esposito R, Capasso E, Savarese G, Casaretti L, Lo Iudice F, Esposito G, Rengo G, Leosco D, Cuocolo A, Perrone-Filardi P. Effects of type 2 diabetes mellitus on coronary microvascular function and myocardial perfusion in patients without obstructive coronary artery disease. *Eur J Nucl Med Mol Imaging* 2012;**39**:1199–1206.
 160. Cruz L, Ryan JJ. Nitric oxide signaling in heart failure with preserved ejection fraction. *JACC Basic Transl Sci* 2017;**2**:341–343.
 161. Sena CM, Pereira AM, Seica R. Endothelial dysfunction—a major mediator of diabetic vascular disease. *Biochim Biophys Acta* 2013;**1832**:2216–2231.
 162. Mátyás C, Németh BT, Oláh A, Török M, Ruppert M, Kellermayer D, Barta BA, Szabó G, Kökény G, Horváth EM, Bódi B, Papp Z, Merkely B, Radovits T. Prevention of the development of heart failure with preserved ejection fraction by the phosphodiesterase-5A inhibitor vardenafil in rats with type 2 diabetes. *Eur J Heart Fail* 2017;**19**:326–336.
 163. Shah MS, Brownlee M. Molecular and cellular mechanisms of cardiovascular disorders in diabetes. *Circ Res* 2016;**118**:1808–1829.
 164. Widyantoro B, Emoto N, Nakayama K, Anggrahini DW, Adiarto S, Iwasa N, Yagi K, Miyagawa K, Rikitake Y, Suzuki T, Kisanuki YY, Yanagisawa M, Hirata K. Endothelial cell-derived endothelin-1 promotes cardiac fibrosis in diabetic hearts through stimulation of endothelial-to-mesenchymal transition. *Circulation* 2010;**121**:2407–2418.
 165. Frati G, Schirone L, Chimenti I, Yee D, Biondi-Zoccai G, Volpe M, Sciarretta S. An overview of the inflammatory signalling mechanisms in the myocardium underlying the development of diabetic cardiomyopathy. *Cardiovasc Res* 2017;**113**:378–388.
 166. Geng H, Guan J. MiR-18a-5p inhibits endothelial-mesenchymal transition and cardiac fibrosis through the Notch2 pathway. *Biochem Biophys Res Commun* 2017;**491**:329–336.
 167. Feng B, Cao Y, Chen S, Chu X, Chu Y, Chakrabarti S. miR-200b mediates endothelial-to-mesenchymal transition in diabetic cardiomyopathy. *Diabetes* 2016;**65**:768–779.
 168. Zhang Y, Dong Y, Xiong Z, Zhu Z, Gao F, Wang T, Man W, Sun D, Lin J, Li T, Li C, Zhao Z, Shen M, Sun D, Fan Y. Sirt6-mediated endothelial-to-mesenchymal transition contributes toward diabetic cardiomyopathy via the Notch1 signaling pathway. *Diabetes Metab Syndr Obes* 2020;**13**:4801–4808.
 169. Du JK, Yu Q, Liu YJ, Du SF, Huang LY, Xu DH, Ni X, Zhu XY. A novel role of kallikrein-related peptidase 8 in the pathogenesis of diabetic cardiac fibrosis. *Theranostics* 2021;**11**:4207–4231.
 170. Li T, Yang GM, Zhu Y, Wu Y, Chen XY, Lan D, Tian KL, Liu LM. Diabetes and hyperlipidemia induce dysfunction of VSMCs: contribution of the metabolic inflammation/miRNA pathway. *Am J Physiol Endocrinol Metab* 2015;**308**:E257–E269.
 171. Sun X, Han F, Yi J, Hou N, Cao Z. The effect of telomerase activity on vascular smooth muscle cell proliferation in type 2 diabetes *in vivo* and *in vitro*. *Mol Med Rep* 2013;**7**:1636–1640.
 172. Deng M, Su D, Xu S, Little PJ, Feng X, Tang L, Shen A. Metformin and vascular diseases: a focused review on smooth muscle cell function. *Front Pharmacol* 2020;**11**:635.
 173. Reddy MA, Das S, Zhuo C, Jin W, Wang M, Lanting L, Natarajan R. Regulation of vascular smooth muscle cell dysfunction under diabetic conditions by miR-504. *Arterioscler Thromb Vasc Biol* 2016;**36**:864–873.
 174. Cifarelli V, Luppi P, Tse HM, He J, Piganelli J, Trucco M. Human proinsulin C-peptide reduces high glucose-induced proliferation and NF- κ B activation in vascular smooth muscle cells. *Atherosclerosis* 2008;**201**:248–257.
 175. Toyohara T, Roudnicki F, Florido MHC, Nakano T, Yu H, Katsuki S, Lee M, Meissner T, Friesen M, Davidow LS, Ptaszek L, Abe T, Rubin LL, Pereira AC, Aikawa M, Cowan CA. Patient hiPSCs identify vascular smooth muscle arylacetamide deacetylase as protective against atherosclerosis. *Cell Stem Cell* 2020;**27**:147–157.e7.
 176. Su H, Cantrell AC, Zeng H, Zhu SH, Chen JX. Emerging role of pericytes and their secretome in the heart. *Cells* 2021;**10**:548.
 177. Warmke N, Griffin KJ, Cubbon RM. Pericytes in diabetes-associated vascular disease. *J Diabetes Complicat* 2016;**30**:1643–1650.
 178. Hammes HP, Du X, Edelstein D, Taguchi T, Matsumura T, Ju Q, Lin J, Bierhaus A, Nawroth P, Hannak D, Neumaier M, Bergfeld R, Giordano I, Brownlee M. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. *Nat Med* 2003;**9**:294–299.
 179. Hinkel R, Howe A, Renner S, Ng J, Lee S, Klett K, Kaczmarek V, Moretti A, Laugwitz KL, Skrobilin P, Mayr M, Milting H, Dendorfer A, Reichart B, Wolf E, Kupatt C. Diabetes mellitus-induced microvascular destabilization in the myocardium. *J Am Coll Cardiol* 2017;**69**:131–143.
 180. Hammes HP, Feng Y, Pfister F, Brownlee M. Diabetic retinopathy: targeting vasoregression. *Diabetes* 2011;**60**:9–16.
 181. Corliss BA, Ray HC, Doty RW, Mathews C, Sheybani N, Fitzgerald K, Prince R, Kelly-Goss MR, Murfee WL, Chappell J, Owens GK, Yates PA, Peirce SM. Pericyte bridges in homeostasis and hyperglycemia. *Diabetes* 2020;**69**:1503–1517.
 182. Maki T, Maeno S, Maeda Y, Yamato M, Sonoda N, Ogawa Y, Wakisaka M, Inoguchi T. Amelioration of diabetic nephropathy by SGLT2 inhibitors independent of its glucose-lowering effect: a possible role of SGLT2 in mesangial cells. *Sci Rep* 2019;**9**:4703.
 183. Wakisaka M, Kitazono T, Kato M, Nakamura U, Yoshioka M, Uchizono Y, Yoshinari M. Sodium-coupled glucose transporter as a functional glucose sensor of retinal microvascular circulation. *Circ Res* 2001;**88**:1183–1188.
 184. Wakisaka M, Kamouchi M, Kitazono T. Lessons from the trials for the desirable effects of sodium glucose co-transporter 2 inhibitors on diabetic cardiovascular events and renal dysfunction. *Int J Mol Sci* 2019;**20**:5668.
 185. Goldberger JJ, Arora R, Buckley U, Shivkumar K. Autonomic nervous system dysfunction: JACC focus seminar. *J Am Coll Cardiol* 2019;**73**:1189–1206.
 186. de Lucia C, Eguchi A, Koch WJ. New insights in cardiac β -adrenergic signaling during heart failure and aging. *Front Pharmacol* 2018;**9**:904.
 187. Grisanti LA. Diabetes and arrhythmias: pathophysiology, mechanisms and therapeutic outcomes. *Front Physiol* 2018;**9**:1669.
 188. Nganou-Gnjindjo CN, Mba CM, Azabji-Kenfack M, Dehayem MY, Mfeukeu-Kuate L, Mbanya JC, Sobngwi E. Poor glycemic control impacts heart rate variability in patients with type 2 diabetes mellitus: a cross sectional study. *BMC Res Notes* 2018;**11**:599.
 189. Vinik AI, Ziegler D. Diabetic cardiovascular autonomic neuropathy. *Circulation* 2007;**115**:387–397.
 190. Agashe S, Petak S. Cardiac autonomic neuropathy in diabetes mellitus. *Methodist Debaque Cardiovasc J* 2018;**14**:251–256.
 191. Ziegler D, Strom A, Straßburger K, Knebel B, Bönhof GJ, Kotzka J, Szendroedi J, Roden M. Association of cardiac autonomic dysfunction with higher levels of plasma lipid metabolites in recent-onset type 2 diabetes. *Diabetologia* 2021;**64**:458–468.
 192. Benichou T, Pereira B, Mermillod M, Tauveron I, Pfabigan D, Magdasy S, Duthel F, Malik RA. Heart rate variability in type 2 diabetes mellitus: a systematic review and meta-analysis. *PLoS One* 2018;**13**:e0195166.
 193. Sacre JW, Franjic B, Jellis CL, Jenkins C, Coombes JS, Marwick TH. Association of cardiac autonomic neuropathy with subclinical myocardial dysfunction in type 2 diabetes. *JACC Cardiovasc Imaging* 2010;**3**:1207–1215.

194. Lee KA, Kim YJ, Park TS, Lee JH, Jin HY. The association between cardiac autonomic neuropathy and heart function in type 2 diabetic patients. *Somatosens Mot Res* 2020; **37**:149–156.
195. Fu Q, Hu Y, Wang Q, Liu Y, Li N, Xu B, Kim S, Chiamvimonvat N, Xiang YK. High-fat diet induces protein kinase A and G-protein receptor kinase phosphorylation of β_2 -adrenergic receptor and impairs cardiac adrenergic reserve in animal hearts. *J Physiol* 2017; **595**:1973–1986.
196. West TM, Wang Q, Deng B, Zhang Y, Barbagallo F, Reddy GR, Chen D, Phan KS, Xu B, Isidori A, Xiang YK. Phosphodiesterase 5 associates with β_2 adrenergic receptor to modulate cardiac function in type 2 diabetic hearts. *J Am Heart Assoc* 2019; **8**:e012273.
197. Tan CMJ, Green P, Tapoulal N, Lewandowski AJ, Leeson P, Herring N. The role of neuropeptide Y in cardiovascular health and disease. *Front Physiol* 2018; **9**:1281.
198. Ejaz A, LoGerfo FW, Pradhan L. Diabetic neuropathy and heart failure: role of neuropeptides. *Expert Rev Mol Med* 2011; **13**:e26.
199. Akiyama N, Okumura K, Watanabe Y, Hashimoto H, Ito T, Ogawa K, Satake T. Altered acetylcholine and norepinephrine concentrations in diabetic rat hearts. Role of parasympathetic nervous system in diabetic cardiomyopathy. *Diabetes* 1989; **38**:231–236.
200. Ganguly PK, Beamish RE, Dhalla KS, Innes IR, Dhalla NS. Norepinephrine storage, distribution, and release in diabetic cardiomyopathy. *Am J Physiol* 1987; **252**:E734–E739.
201. Duncan BB, Schmidt MI, Pankow JS, Ballantyne CM, Couper D, Vigo A, Hoogeveen R, Folsom AR, Heiss G. Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. *Diabetes* 2003; **52**:1799–1805.
202. Prabhu SD, Frangogiannis NG. The biological basis for cardiac repair after myocardial infarction: from inflammation to fibrosis. *Circ Res* 2016; **119**:91–112.
203. Mann DL. Innate immunity and the failing heart: the cytokine hypothesis revisited. *Circ Res* 2015; **116**:1254–1268.
204. Frieler RA, Mortensen RM. Immune cell and other noncardiomyocyte regulation of cardiac hypertrophy and remodeling. *Circulation* 2015; **131**:1019–1030.
205. Filardi T, Ghinassi B, Di Baldassarre A, Tanzilli G, Morano S, Lenzi A, Basili S, Crescioli C. Cardiomyopathy associated with diabetes: the central role of the cardiomyocyte. *Int J Mol Sci* 2019; **20**:3299.
206. DeBerge M, Shah SJ, Wilsbacher L, Thorp EB. Macrophages in heart failure with reduced versus preserved ejection fraction. *Trends Mol Med* 2019; **25**:328–340.
207. Yu X-Y, Chen H-M, Liang J-L, Lin Q-X, Tan H-H, Fu Y-H, Liu X-Y, Shan Z-X, Li X-H, Yang H-Z, Yang M, Li Y, Lin S-G, Fadini GP. Hyperglycemic myocardial damage is mediated by proinflammatory cytokine: macrophage migration inhibitory factor. *PLoS One* 2011; **6**:e16239.
208. Hernandez-Mijares A, Rocha M, Rovira-Llopis S, Bañuls C, Bellod L, de Pablo C, Alvarez A, Roldan-Torres I, Sola-Izquierdo E, Victor VM. Human leukocyte/endothelial cell interactions and mitochondrial dysfunction in type 2 diabetic patients and their association with silent myocardial ischemia. *Diabetes Care* 2013; **36**:1695–1702.
209. Bajpai A, Tilley DG. The role of leukocytes in diabetic cardiomyopathy. *Front Physiol* 2018; **9**:1547.
210. Pierzynová A, Šrámek J, Cinkajlová A, Kratochvilová H, Lindner J, Haluzik M, Kučera T. The number and phenotype of myocardial and adipose tissue CD68⁺ cells is associated with cardiovascular and metabolic disease in heart surgery patients. *Nutr Metab Cardiovasc Dis* 2019; **29**:946–955.
211. Nan WQ, Shan TQ, Qian X, Ping W, Bing GA, Ying LL. PPAR α agonist prevented the apoptosis induced by glucose and fatty acid in neonatal cardiomyocytes. *J Endocrinol Invest* 2011; **34**:271–275.
212. Hong L-F, Li X-L, Luo S-H, Guo Y-L, Liu J, Zhu C-G, Qing P, Xu R-X, Wu N-Q, Jiang L-X, Li J-J, Vergani A. Relation of leukocytes and its subsets counts with the severity of stable coronary artery disease in patients with diabetic mellitus. *PLoS One* 2014; **9**:e90663.
213. Kondo M. Lymphoid and myeloid lineage commitment in multipotent hematopoietic progenitors. *Immunol Rev* 2010; **238**:37–46.
214. Horckmans M, Ring L, Duchene J, Santovito D, Schloss MJ, Drechsler M, Weber C, Soehnlein O, Steffens S. Neutrophils orchestrate post-myocardial infarction healing by polarizing macrophages towards a reparative phenotype. *Eur Heart J* 2017; **38**:187–197.
215. Wong SL, Demers M, Martinod K, Gallant M, Wang Y, Goldfine AB, Kahn CR, Wagner DD. Diabetes primes neutrophils to undergo NETosis, which impairs wound healing. *Nat Med* 2015; **21**:815–819.
216. Fadini GP, Menegazzo L, Scattolini V, Gintoli M, Albiero M, Avogaro A. A perspective on NETosis in diabetes and cardiometabolic disorders. *Nutr Metab Cardiovasc Dis* 2016; **26**:1–8.
217. Huang X, Qin Z, Xu M, Zhang F, Jiang X, Hua F, Tao L. Neutrophil: lymphocyte ratio is positively associated with subclinical diabetic cardiomyopathy. *BMC Endocr Disord* 2020; **20**:99.
218. Watanabe R, Hilhorst M, Zhang H, Zeisbrich M, Berry GJ, Wallis BB, Harrison DG, Giacomini JC, Goronzy JJ, Weyand CM. Glucose metabolism controls disease-specific signatures of macrophage effector functions. *JCI Insight* 2018; **3**:e123047.
219. Khanna S, Biswas S, Shang Y, Collard E, Azad A, Kauh C, Bhaskar V, Gordillo GM, Sen CK, Roy S. Macrophage dysfunction impairs resolution of inflammation in the wounds of diabetic mice. *PLoS One* 2010; **5**:e9539.
220. McManus LM, Bloodworth RC, Prihoda TJ, Blodgett JL, Pinckard RN. Agonist-dependent failure of neutrophil function in diabetes correlates with extent of hyperglycemia. *J Leukoc Biol* 2001; **70**:395–404.
221. Neethi Raj P, Shaji BV, Haritha VH, Anie Y. Neutrophil secretion modulates neutrophil and monocyte functions during hyperglucose and/or hyperinsulin conditions in vitro. *J Cell Immunother* 2018; **4**:65–70.
222. Alba-Loureiro TC, Hirabara SM, Mendonça JR, Curi R, Pithon-Curi TC. Diabetes causes marked changes in function and metabolism of rat neutrophils. *J Endocrinol* 2006; **188**:295–303.
223. Jakelić J, Kokić S, Hozo I, Maras J, Fabijanić D. Nonspecific immunity in diabetes: hyperglycemia decreases phagocytic activity of leukocytes in diabetic patients. *Med Arh* 1995; **49**:9–12.
224. Xue J, Schmidt SV, Sander J, Draffehn A, Krebs W, Quester I, De Nardo D, Gohel TD, Emde M, Schmidleithner L, Ganesan H, Nino-Castro A, Mallmann MR, Labzin L, Theis H, Kraut M, Beyer M, Latz E, Freeman TC, Ulas T, Schultze JL. Transcriptome-based network analysis reveals a spectrum model of human macrophage activation. *Immunity* 2014; **40**:274–288.
225. Piccolo V, Curina A, Genua M, Ghisletti S, Simonatto M, Sabò A, Amati B, Ostuni R, Natoli G. Opposing macrophage polarization programs show extensive epigenomic and transcriptional cross-talk. *Nat Immunol* 2017; **18**:530–540.
226. Lurier EB, Dalton D, Dampier W, Raman P, Nassiri S, Ferraro NM, Rajagopalan R, Sarmady M, Spiller KL. Transcriptome analysis of IL-10-stimulated (M2c) macrophages by next-generation sequencing. *Immunobiology* 2017; **222**:847–856.
227. Glanz V, Myasoedova VA, Sukhorukov V, Grechko A, Zhang D, Romanenko EB, Orekhova VA, Orekhov A. Transcriptional characteristics of activated macrophages. *Curr Pharm Des* 2019; **25**:213–217.
228. Rao X, Zhong J, Sun Q. The heterogenic properties of monocytes/macrophages and neutrophils in inflammatory response in diabetes. *Life Sci* 2014; **116**:59–66.
229. Liu G, Yan D, Yang L, Sun Y, Zhan L, Lu L, Jin Z, Zhang C, Long P, Chen J, Yuan Q. The effect of miR-471-3p on macrophage polarization in the development of diabetic cardiomyopathy. *Life Sci* 2021; **268**:118989.
230. Jin L, Deng Z, Zhang J, Yang C, Liu J, Han W, Ye P, Si Y, Chen G. Mesenchymal stem cells promote type 2 macrophage polarization to ameliorate the myocardial injury caused by diabetic cardiomyopathy. *J Transl Med* 2019; **17**:251.
231. Singla DK, Singla RD, Abdelli LS, Glass C, Tang Y. Fibroblast growth factor-9 enhances M2 macrophage differentiation and attenuates adverse cardiac remodeling in the infarcted diabetic heart. *PLoS One* 2015; **10**:e0120739.
232. Urbina P, Singla DK. BMP-7 attenuates adverse cardiac remodeling mediated through M2 macrophages in prediabetic cardiomyopathy. *Am J Physiol Heart Circ Physiol* 2014; **307**:H762–H772.
233. Kanter JE, Kramer F, Barnhart S, Averill MM, Vivekanandan-Giri A, Vickery T, Li LO, Becker L, Yuan W, Chait A, Braun KR, Potter-Perigo S, Sanda S, Wight TN, Pennathur S, Serhan CN, Heinecke JW, Coleman RA, Bornfeldt KE. Diabetes promotes an inflammatory macrophage phenotype and atherosclerosis through acyl-CoA synthetase 1. *Proc Natl Acad Sci U S A* 2012; **109**:E715–E724.
234. Mouton AJ, Li X, Hall ME, Hall JE. Obesity, hypertension, and cardiac dysfunction: novel roles of immunometabolism in macrophage activation and inflammation. *Circ Res* 2020; **126**:789–806.
235. Jia G, Habibi J, Bostick BP, Ma L, DeMarco VG, Aroor AR, Hayden MR, Whaley-Connell AT, Sowers JR. Uric acid promotes left ventricular diastolic dysfunction in mice fed a Western diet. *Hypertension* 2015; **65**:531–539.
236. Asrih M, Mach F, Nencioni A, Dallegri F, Quercioli A, Montecucco F. Role of mitogen-activated protein kinase pathways in multifactorial adverse cardiac remodeling associated with metabolic syndrome. *Mediators Inflamm* 2013; **2013**:367245.
237. Babu S S, Thandavarayan RA, Joladarashi D, Jeyabal P, Krishnamurthy S, Bhimaraj A, Youker KA, Krishnamurthy P. MicroRNA-126 overexpression rescues diabetes-induced impairment in efferocytosis of apoptotic cardiomyocytes. *Sci Rep* 2016; **6**:36207.
238. Zeng C, Shi X, Zhang B, Liu H, Zhang L, Ding W, Zhao Y. The imbalance of Th17/Th1/Tregs in patients with type 2 diabetes: relationship with metabolic factors and complications. *J Mol Med (Berl)* 2012; **90**:175–186.
239. Zhang C, Xiao C, Wang P, Xu W, Zhang A, Li Q, Xu X. The alteration of Th1/Th2/Th17/Treg paradigm in patients with type 2 diabetes mellitus: relationship with diabetic nephropathy. *Hum Immunol* 2014; **75**:289–296.
240. Nevers T, Salvador AM, Grodecki-Pena A, Knapp A, Velázquez F, Aronovitz M, Kapur NK, Karas RH, Blanton RM, Alcáide P. Left ventricular t-cell recruitment contributes to the pathogenesis of heart failure. *Circ Heart Fail* 2015; **8**:776–787.
241. Zhao R, Tang D, Yi S, Li W, Wu C, Lu Y, Hou X, Song J, Lin P, Chen L, Sun L, Lobaccaro J-MA. Elevated peripheral frequencies of Th22 cells: a novel potent participant in obesity and type 2 diabetes. *PLoS One* 2014; **9**:e85770.
242. Madhumitha H, Mohan V, Deepa M, Babu S, Aravindhan V. Increased Th1 and suppressed Th2 serum cytokine levels in subjects with diabetic coronary artery disease. *Cardiovasc Diabetol* 2014; **13**:1.
243. Wu D, Molofsky AB, Liang HE, Ricardo-Gonzalez RR, Jouihan HA, Bando JK, Chawla A, Locksley RM. Eosinophils sustain adipose alternatively activated macrophages associated with glucose homeostasis. *Science* 2011; **332**:243–247.
244. Bluestone JA, Buckner JH, Fitch M, Gitelman SE, Gupta S, Hellerstein MK, Herold KC, Lares A, Lee MR, Li K, Liu W, Long SA, Masiello LM, Nguyen V, Putnam AL, Rieck M, Sayre PH, Tang Q. Type 1 diabetes immunotherapy using polyclonal regulatory T cells. *Sci Transl Med* 2015; **7**:315ra189.

245. Li J, Wang L, Wang S, Zhu H, Ye P, Xie A, Shen B, Liu C, Guo C, Fu Q, Zhang K, Xia J. The Treg/Th17 imbalance in patients with idiopathic dilated cardiomyopathy. *Scand J Immunol* 2010;**71**:298–303.
246. Venkatachalam K, Venkatesan B, Valente AJ, Melby PC, Nandish S, Reusch JE, Clark RA, Chandrasekar B. WISP1, a pro-mitogenic, pro-survival factor, mediates tumor necrosis factor- α (TNF- α)-stimulated cardiac fibroblast proliferation but inhibits TNF- α -induced cardiomyocyte death. *J Biol Chem* 2009;**284**:14414–14427.
247. Honsho S, Nishikawa S, Amano K, Zen K, Adachi Y, Kishita E, Matsui A, Katsume A, Yamaguchi S, Nishikawa K, Isoda K, Riches DW, Matoba S, Okigaki M, Matsubara H. Pressure-mediated hypertrophy and mechanical stretch induces IL-1 release and subsequent IGF-1 generation to maintain compensative hypertrophy by affecting Akt and JNK pathways. *Circ Res* 2009;**105**:1149–1158.
248. Vierhout M, Ayoub A, Naiel S, Yazdanshenas P, Revell SD, Reihani A, Dvorkin-Gheva A, Shi W, Ask K. Monocyte and macrophage derived myofibroblasts: is it fate? A review of the current evidence. *Wound Repair Regen* 2021;**29**:548–562.
249. Haider N, Boscá L, Zandbergen HR, Kovacic JC, Narula N, González-Ramos S, Fernandez-Velasco M, Agrawal S, Paz-García M, Gupta S, DeLeon-Pennell K, Fuster V, Ibañez B, Narula J. Transition of macrophages to fibroblast-like cells in healing myocardial infarction. *J Am Coll Cardiol* 2019;**74**:3124–3135.
250. Torres Á, Muñoz K, Nahuelpan Y, Saez APR, Mendoza P, Jara C, Cappelli C, Suarez R, Oyarzún C, Quezada C, San Martín R. Intraglomerular monocyte/macrophage infiltration and macrophage-myofibroblast transition during diabetic nephropathy is regulated by the A_{2B} adenosine receptor. *Cells* 2020;**9**:1051.
251. Sinha M, Sen CK, Singh K, Das A, Ghatak S, Rhea B, Blackstone B, Powell HM, Khanna S, Roy S. Direct conversion of injury-site myeloid cells to fibroblast-like cells of granulation tissue. *Nat Commun* 2018;**9**:936.
252. Yáñez-Mó M, Siljander PR-M, Andreu Z, Zavec AB, Borrás FE, Buzas EI, Buzas K, Casal E, Cappello F, Carvalho J, Colás E, Cordeiro-da Silva A, Fais S, Falcon-Perez JM, Ghoobrial IM, Giebel B, Gimona M, Graner M, Gursel I, Gursel M, Heegaard NHH, Hendrix A, Kierulff P, Kokubun K, Kosanovic M, Králj-Iglic V, Krämer-Albers E-M, Laitinen S, Lässer C, Lener T, Ligeti E, Liné A, Lipps G, Llorente A, Lötvall J, Manček-Keber M, Marcilla A, Mittelbrunn M, Nazarenko I, Nolte-t Hoen ENM, Nyman TA, O'Driscoll L, Olivan M, Oliveira C, Pállinger É, Del Portillo HA, Reventós J, Rigau M, Rohde E, Sammar M, Sánchez-Madrid F, Santarém N, Schallmoser K, Ostendorf MS, Stoorvogel W, Stukelj R, Van der Grein SG, Vasconcelos MH, Wauben MHM, De Wever O. Biological properties of extracellular vesicles and their physiological functions. *J Extracell Vesicles* 2015;**4**:27066.
253. Fu S, Zhang Y, Li Y, Luo L, Zhao Y, Yao Y. Extracellular vesicles in cardiovascular diseases. *Cell Death Discov* 2020;**6**:68.
254. Salem ESB, Fan GC. Pathological effects of exosomes in mediating diabetic cardiomyopathy. *Adv Exp Med Biol* 2017;**998**:113–138.
255. Gustafson D, Veitch S, Fish JE. Extracellular vesicles as protagonists of diabetic cardiovascular pathology. *Front Cardiovasc Med* 2017;**4**:71.
256. Prattichizzo F, De Nigris V, Sabbatini J, Giuliani A, Castaño C, Párrizas M, Crespo I, Grimaldi A, Baranzini N, Spiga R, Mancuso E, Rippo MR, Procopio AD, Novials A, Bonfigli AR, Garavelli S, La Sala L, Matarese G, de Candia P, Olivieri F, Ciriello A. CD31⁺ extracellular vesicles from patients with type 2 diabetes shuttle a miRNA signature associated with cardiovascular complications. *Diabetes* 2021;**70**:240–254.
257. Feng B, Chen Y, Luo Y, Chen M, Li X, Ni Y. Circulating level of microparticles and their correlation with arterial elasticity and endothelium-dependent dilation in patients with type 2 diabetes mellitus. *Atherosclerosis* 2010;**208**:264–269.
258. Koga H, Sugiyama S, Kugiyama K, Watanabe K, Fukushima H, Tanaka T, Sakamoto T, Yoshimura M, Jinnouchi H, Ogawa H. Elevated levels of VE-cadherin-positive endothelial microparticles in patients with type 2 diabetes mellitus and coronary artery disease. *J Am Coll Cardiol* 2005;**45**:1622–1630.
259. Karolina DS, Tavintharan S, Armugam A, Sepramaniam S, Pek SL, Wong MT, Lim SC, Sum CF, Jeyaseelan K. Circulating miRNA profiles in patients with metabolic syndrome. *J Clin Endocrinol Metab* 2012;**97**:E2271–E2276.
260. Jansen F, Wang H, Przybilla D, Franklin BS, Dolf A, Pfeifer P, Schmitz T, Flender A, Endl E, Nickenig G, Werner N. Vascular endothelial microparticles-incorporated microRNAs are altered in patients with diabetes mellitus. *Cardiovasc Diabetol* 2016;**15**:49.
261. Wang X, Huang W, Liu G, Cai W, Millard RW, Wang Y, Chang J, Peng T, Fan GC. Cardiomyocytes mediate anti-angiogenesis in type 2 diabetic rats through the exosomal transfer of miR-320 into endothelial cells. *J Mol Cell Cardiol* 2014;**74**:139–150.
262. Zampetaki A, Kiechl S, Drozdov I, Willeit P, Mayr U, Prokopi M, Mayr A, Weger S, Oberholzer F, Bonora E, Shah A, Willeit J, Mayr M. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. *Circ Res* 2010;**107**:810–817.
263. Jansen F, Yang X, Hoelscher M, Cattelan A, Schmitz T, Proebsting S, Wenzel D, Vosen S, Franklin BS, Fleischmann BK, Nickenig G, Werner N. Endothelial microparticle-mediated transfer of MicroRNA-126 promotes vascular endothelial cell repair via SPRED1 and is abrogated in glucose-damaged endothelial microparticles. *Circulation* 2013;**128**:2026–2038.
264. Wu K, Yang Y, Zhong Y, Ammar HM, Zhang P, Guo R, Liu H, Cheng C, Koroscil TM, Chen Y, Liu S, Bihl JC. The effects of microvesicles on endothelial progenitor cells are compromised in type 2 diabetic patients via downregulation of the miR-126/VEGFR2 pathway. *Am J Physiol Endocrinol Metab* 2016;**310**:E828–E837.
265. Caporali A, Meloni M, Nailor A, Mitic T, Shantikumar S, Riu F, Sala-Newby GB, Rose L, Besnier M, Katare R, Voellenkle C, Verkade P, Martelli F, Madeddu P, Emanueli C. p75NTR-dependent activation of NF- κ B regulates microRNA-503 transcription and pericyte–endothelial crosstalk in diabetes after limb ischaemia. *Nat Commun* 2015;**6**:8024.
266. Zhang H, Liu J, Qu D, Wang L, Wong CM, Lau CW, Huang Y, Wang YF, Huang H, Xia Y, Xiang L, Cai Z, Liu P, Wei Y, Yao X, Ma RCW, Huang Y. Serum exosomes mediate delivery of arginase 1 as a novel mechanism for endothelial dysfunction in diabetes. *Proc Natl Acad Sci U S A* 2018;**115**:E6927–E6936.
267. Bang C, Batkai S, Dangwal S, Gupta SK, Foinquinos A, Holzmann A, Just A, Remke J, Zimmer K, Zeug A, Ponimaskin E, Schmiedl A, Yin X, Mayr M, Halder R, Fischer A, Engelhardt S, Wei Y, Schober A, Fiedler J, Thum T. Cardiac fibroblast-derived microRNA passenger strand-enriched exosomes mediate cardiomyocyte hypertrophy. *J Clin Invest* 2014;**124**:2136–2146.
268. Jakubik D, Fitas A, Eyleten C, Jarosz-Popek J, Nowak A, Czajka P, Wicik Z, Sourij H, Siller-Matula JM, De Rosa S, Postula M. MicroRNAs and long non-coding RNAs in the pathophysiological processes of diabetic cardiomyopathy: emerging biomarkers and potential therapeutics. *Cardiovasc Diabetol* 2021;**20**:55.
269. Guo Y, Feng X, Wang D, Kang X, Zhang L, Ren H, Yuan G. Long non-coding RNA: a key regulator in the pathogenesis of diabetic cardiomyopathy. *Front Cardiovasc Med* 2021;**8**:655598.
270. Zhang W, Xu W, Feng Y, Zhou X. Non-coding RNA involvement in the pathogenesis of diabetic cardiomyopathy. *J Cell Mol Med* 2019;**23**:5859–5867.
271. Li X, Wang H, Yao B, Xu W, Chen J, Zhou X. lncRNA H19/miR-675 axis regulates cardiomyocyte apoptosis by targeting VDAC1 in diabetic cardiomyopathy. *Sci Rep* 2016;**6**:36340.
272. Yang F, Qin Y, Lv J, Wang Y, Che H, Chen X, Jiang Y, Li A, Sun X, Yue E, Ren L, Li Y, Bai Y, Wang L. Silencing long non-coding RNA Kcnq1ot1 alleviates pyroptosis and fibrosis in diabetic cardiomyopathy. *Cell Death Dis* 2018;**9**:1000.
273. Yang F, Qin Y, Wang Y, Li A, Lv J, Sun X, Che H, Han T, Meng S, Bai Y, Wang L. lncRNA KCNQ1OT1 mediates pyroptosis in diabetic cardiomyopathy. *Cell Physiol Biochem* 2018;**50**:1230–1244.
274. Tanwar VS, Reddy MA, Natarajan R. Emerging role of long non-coding RNAs in diabetic vascular complications. *Front Endocrinol (Lausanne)* 2021;**12**:665811.
275. Reddy MA, Chen Z, Park JT, Wang M, Lanting L, Zhang Q, Bhatt K, Leung A, Wu X, Putta S, Sætrum P, Devaraj S, Natarajan R. Regulation of inflammatory phenotype in macrophages by a diabetes-induced long noncoding RNA. *Diabetes* 2014;**63**:4249–4261.
276. Reddy MA, Amaram V, Das S, Tanwar VS, Ganguly R, Wang M, Lanting L, Zhang L, Abdollahi M, Chen Z, Wu X, Devaraj S, Natarajan R. lncRNA DRAIR is downregulated in diabetic monocytes and modulates the inflammatory phenotype via epigenetic mechanisms. *JCI Insight* 2021;**6**:e143289.
277. Gao L, Wang X, Guo S, Xiao L, Liang C, Wang Z, Li Y, Liu Y, Yao R, Liu Y, Zhang Y. lncRNA HOTAIR functions as a competing endogenous RNA to upregulate SIRT1 by sponging miR-34a in diabetic cardiomyopathy. *J Cell Physiol* 2019;**234**:4944–4958.
278. Zhang M, Gu H, Chen J, Zhou X. Involvement of long noncoding RNA MALAT1 in the pathogenesis of diabetic cardiomyopathy. *Int J Cardiol* 2016;**202**:753–755.
279. Zhou X, Zhang W, Jin M, Chen J, Xu W, Kong X. lncRNA MIAT functions as a competing endogenous RNA to upregulate DAPK2 by sponging miR-22-3p in diabetic cardiomyopathy. *Cell Death Dis* 2017;**8**:e2929.
280. Qi Y, Wu H, Mai C, Lin H, Shen J, Zhang X, Gao Y, Mao Y, Xie X. lncRNA-MIAT-mediated miR-214-3p silencing is responsible for IL-17 production and cardiac fibrosis in diabetic cardiomyopathy. *Front Cell Dev Biol* 2020;**8**:243.
281. Zheng D, Zhang Y, Hu Y, Guan J, Xu L, Xiao W, Zhong Q, Ren C, Lu J, Liang J, Hou J. Long noncoding RNA Crnde attenuates cardiac fibrosis via Smad3-Crnde negative feedback in diabetic cardiomyopathy. *FEBS J* 2019;**286**:1645–1655.
282. Zhao L, Li W, Zhao H. Inhibition of long non-coding RNA TUG1 protects against diabetic cardiomyopathy induced diastolic dysfunction by regulating miR-499-5p. *Am J Transl Res* 2020;**12**:718–730.
283. Tang C-M, Zhang M, Huang L, Hu Z-Q, Zhu J-N, Xiao Z, Zhang Z, Lin Q-X, Zheng X-L, Yang M, Wu S-L, Cheng J-D, Shan Z-X. CircRNA_000203 enhances the expression of fibrosis-associated genes by derepressing targets of miR-26b-5p, Col1a2 and CTGF, in cardiac fibroblasts. *Sci Rep* 2017;**7**:40342.
284. Zhou B, Yu JW. A novel identified circular RNA, circRNA_010567, promotes myocardial fibrosis via suppressing miR-141 by targeting TGF- β 1. *Biochem Biophys Res Commun* 2017;**487**:769–775.
285. Pant T, Dhanasekaran A, Zhao M, Thorp EB, Forbess JM, Bosnjak ZJ, Benjamin IJ, Ge ZD. Identification and analysis of circulating long non-coding RNAs with high significance in diabetic cardiomyopathy. *Sci Rep* 2021;**11**:2571.
286. Chen Y, Tan S, Liu M, Li J. lncRNA TINCR is downregulated in diabetic cardiomyopathy and relates to cardiomyocyte apoptosis. *Scand Cardiovasc J* 2018;**52**:335–339.
287. Li Q, Li P, Su J, Liu S, Yang X, Yang Y, Niu S. lncRNA NKILA was upregulated in diabetic cardiomyopathy with early prediction values. *Exp Ther Med* 2019;**18**:1221–1225.
288. Lawson C, Vicencio JM, Yellon DM, Davidson SM. Microvesicles and exosomes: new players in metabolic and cardiovascular disease. *J Endocrinol* 2016;**228**:R57–R71.
289. Castaño C, Novials A, Párrizas M. Exosomes and diabetes. *Diabetes Metab Res Rev* 2019;**35**:e3107.

290. Xie Z, Wang X, Liu X, Du H, Sun C, Shao X, Tian J, Gu X, Wang H, Tian J, Yu B. Adipose-derived exosomes exert proatherogenic effects by regulating macrophage foam cell formation and polarization. *J Am Heart Assoc* 2018;**7**:e007442.
291. Song M, Han L, Chen FF, Wang D, Wang F, Zhang L, Wang ZH, Zhong M, Tang MX, Zhang W. Adipocyte-derived exosomes carrying sonic hedgehog mediate M1 macrophage polarization-induced insulin resistance via pthch and PI3K pathways. *Cell Physiol Biochem* 2018;**48**:1416–1432.
292. Ying W, Riopel M, Bandyopadhyay G, Dong Y, Birmingham A, Seo JB, Ofrecio JM, Wollam J, Hernandez-Carretero A, Fu W, Li P, Olefsky JM. Adipose tissue macrophage-derived exosomal miRNAs can modulate *in vivo* and *in vitro* insulin sensitivity. *Cell* 2017;**171**:372–384.e12.
293. Tao L, Shi J, Yang X, Yang L, Hua F. The exosome: a new player in diabetic cardiomyopathy. *J Cardiovasc Transl Res* 2019;**12**:62–67.
294. Wang X, Gu H, Huang W, Peng J, Li Y, Yang L, Qin D, Essandoh K, Wang Y, Peng T, Fan GC. Hsp20-mediated activation of exosome biogenesis in cardiomyocytes improves cardiac function and angiogenesis in diabetic mice. *Diabetes* 2016;**65**:3111–3128.
295. Bugger H, Abel ED. Rodent models of diabetic cardiomyopathy. *Dis Model Mech* 2009;**2**:454–466.
296. Riehl C, Bauersachs J. Of mice and men: models and mechanisms of diabetic cardiomyopathy. *Basic Res Cardiol* 2018;**114**:2.
297. Tate M, Prakoso D, Willis AM, Peng C, Deo M, Qin CX, Walsh JL, Nash DM, Cohen CD, Rofo AK, Sharma A, Kiriazis H, Donner DG, De Haan JB, Watson AMD, De Blasio MJ, Ritchie RH. Characterising an alternative murine model of diabetic cardiomyopathy. *Front Physiol* 2019;**10**:1395.
298. Heydemann A. An overview of murine high fat diet as a model for type 2 diabetes mellitus. *J Diabetes Res* 2016;**2016**:2902351.
299. Wang Y, Luo W, Han J, Khan ZA, Fang Q, Jin Y, Chen X, Zhang Y, Wang M, Qian J, Huang W, Lum H, Wu G, Liang G. MD2 activation by direct AGE interaction drives inflammatory diabetic cardiomyopathy. *Nat Commun* 2020;**11**:2148.
300. Dong F, Zhang X, Yang X, Esberg LB, Yang H, Zhang Z, Culver B, Ren J. Impaired cardiac contractile function in ventricular myocytes from leptin-deficient ob/ob obese mice. *J Endocrinol* 2006;**188**:25–36.
301. Costa GC, Montagnoli TL, Da Silva JS, de Alencar AKN, Reina Gamba LE, Alves BEO, da Silva MMC, Trachez MM, do Nascimento JHM, Pimentel-Coelho PM, Mendez-Otero R, Lima LM, Barreiro EJ, Sudo RT, Zapata-Sudo G. New benzofuran N-acylhydrazones reduces cardiovascular dysfunction in obese rats by blocking TNF- α synthesis. *Drug Des Devel Ther* 2020;**14**:3337–3350.
302. Cefalu WT. Animal models of type 2 diabetes: clinical presentation and pathophysiological relevance to the human condition. *ILAR J* 2006;**47**:186–198.
303. Greenberg MJ, Daily NJ, Wang A, Conway MK, Wakatsuki T. Genetic and tissue engineering approaches to modeling the mechanics of human heart failure for drug discovery. *Front Cardiovasc Med* 2018;**5**:120.
304. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E, Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. *N Engl J Med* 2015;**373**:232–242.
305. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiwiot D, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. *N Engl J Med* 2013;**369**:1317–1326.
306. Ribeiro AJS, Guth BD, Engwall M, Eldridge S, Foley CM, Guo L, Gintant G, Koerner J, Parish ST, Pierson JB, Brock M, Chaudhary KW, Kanda Y, Berridge B. Considerations for an *in vitro*, cell-based testing platform for detection of drug-induced inotropic effects in early drug development. Part 2: designing and fabricating microsystems for assaying cardiac contractility with physiological relevance using human iPSC-cardiomyocytes. *Front Pharmacol* 2019;**10**:934.
307. Parrotta EI, Lucchino V, Scaramuzzino L, Scalise S, Cuda G. Modeling cardiac disease mechanisms using induced pluripotent stem cell-derived cardiomyocytes: progress, promises and challenges. *Int J Mol Sci* 2020;**21**:4354.
308. Tang L, Wang H, Dai B, Wang X, Zhou D, Shen J, Guo F, Wang J, Zhou J, Wang H, Wu Q, Yao H, Gong T, Su J, Meng ZX, Niu T, Zhang L, Liang P. Human induced pluripotent stem cell-derived cardiomyocytes reveal abnormal TGF β signaling in type 2 diabetes mellitus. *J Mol Cell Cardiol* 2020;**142**:53–64.
309. Mills RJ, Parker BL, Quaife-Ryan GA, Vokes HG, Needham EJ, Bornot A, Ding M, Andersson H, Polla M, Elliott DA, Drowley L, Clausen M, Plowright AT, Barrett IP, Wang QD, James DE, Porrello ER, Hudson JE. Drug screening in human PSC-cardiac organoids identifies pro-proliferative compounds acting via the mevalonate pathway. *Cell Stem Cell* 2019;**24**:895–907.e6.
310. Titmarsh DM, Glass NR, Mills RJ, Hidalgo A, Wolvetang EJ, Porrello ER, Hudson JE, Cooper-White JJ. Induction of human iPSC-derived cardiomyocyte proliferation revealed by combinatorial screening in high density microbio-reactor arrays. *Sci Rep* 2016;**6**:24637.
311. Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, Jones JM. Embryonic stem cell lines derived from human blastocysts. *Science* 1998;**282**:1145–1147.
312. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell* 2007;**131**:861–872.
313. Wilmut I, Leslie S, Martin NG, Peschanski M, Rao M, Trounson A, Turner D, Turner ML, Yamanaka S, Taylor CJ. Development of a global network of induced pluripotent stem cell haplobanks. *Regen Med* 2015;**10**:235–238.
314. Sullivan S, Ginty P, McMahon S, May M, Solomon SL, Kurtz A, Stacey GN, Bennaceur Griscelli A, Li RA, Barry J, Song J, Turner ML. The global alliance for iPSC therapies (GAIIT). *Stem Cell Res* 2020;**49**:102036.
315. Lee S, Huh JY, Turner DM, Lee S, Robinson J, Stein JE, Shim SH, Hong CP, Kang MS, Nakagawa M, Kaneko S, Nakanishi M, Rao MS, Kurtz A, Stacey GN, Marsh SGE, Turner ML, Song J. Repurposing the cord blood bank for haplobanking of HLA-homozygous iPSCs and their usefulness to multiple populations. *Stem Cells* 2018;**36**:1552–1566.
316. Drawnel FM, Boccardo S, Prummer M, Delobel F, Graff A, Weber M, Gérard R, Badi L, Kam-Thong T, Bu L, Jiang X, Hoffack JC, Kiialainen A, Jeworutzki E, Aoyama N, Carlson C, Burcin M, Gromo G, Boehringer M, Stahlberg H, Hall BJ, Magnone MC, Kolaja K, Chien KR, Bailly J, Iacone R. Disease modeling and phenotypic drug screening for diabetic cardiomyopathy using human induced pluripotent stem cells. *Cell Rep* 2014;**9**:810–821.
317. Ng KM, Lau YM, Dhandhanva V, Cai ZJ, Lee YK, Lai WH, Tse HF, Siu CW. Empagliflozin ameliorates high glucose induced-cardiac dysfunction in human iPSC-derived cardiomyocytes. *Sci Rep* 2018;**8**:14872.
318. Granéli C, Hicks R, Brölén G, Synnergren J, Sartipy P. Diabetic cardiomyopathy modeling using induced pluripotent stem cell derived cardiomyocytes: recent advances and emerging models. *Stem Cell Rev Rep* 2019;**15**:13–22.
319. Canfield SG, Zaja I, Godshaw B, Twaroski D, Bai X, Bosnjak ZJ. High glucose attenuates anesthetic cardioprotection in stem-cell-derived cardiomyocytes: the role of reactive oxygen species and mitochondrial fission. *Anesth Analg* 2016;**122**:1269–1279.
320. Prakoso D, Lim SY, Erickson JR, Wallace RS, Lees JG, Tate M, Kiriazis H, Donner DG, Henstridge DC, Davey JR, Qian H, Deo M, Parry LJ, Davidoff AJ, Gregorevic P, Chatham JC, De Blasio MJ, Ritchie RH. Fine-tuning the cardiac O-GlcNAcylation regulatory enzymes governs the functional and structural phenotype of the diabetic heart. *Cardiovasc Res* 2022;**118**:212–225.
321. Bekhte M, González-Delgado A, Hübner S, Haxhikadrija P, Kretzschmar T, Müller T, Wu JMF, Bekfani T, Franz M, Wartenberg M, Gräler M, Greber B, Schulze PC. The role of ceramide accumulation in human induced pluripotent stem cell-derived cardiomyocytes on mitochondrial oxidative stress and mitophagy. *Free Radic Biol Med* 2021;**167**:66–80.
322. Su L, Kong X, Loo SJ, Gao Y, Kovalik JP, Su X, Ma J, Ye L. Diabetic endothelial cells differentiated from patient iPSCs show dysregulated glycine homeostasis and senescence associated phenotypes. *Front Cell Dev Biol* 2021;**9**:667252.
323. Ong SB, Lee WH, Shao NY, Ismail NI, Katwadi K, Lim MM, Kwek XY, Michel NA, Li J, Newson J, Tahmasebi S, Rehman J, Kodo K, Jang HR, Ong SG. Calpain inhibition restores autophagy and prevents mitochondrial fragmentation in a human iPSC model of diabetic endotheliopathy. *Stem Cell Rep* 2019;**12**:597–610.
324. Balistreri M, Davis JA, Campbell KF, Da Rocha AM, Treadwell MC, Herron TJ. Effect of glucose on 3D cardiac microtissues derived from human induced pluripotent stem cells. *Pediatr Cardiol* 2017;**38**:1575–1582.
325. Lewis-Israeli YR, Wasserman AH, Gabalski MA, Volmert BD, Ming Y, Ball KA, Yang W, Zou J, Ni G, Pajares N, Chatzistavrou X, Li W, Zhou C, Aguirre A. Self-assembling human heart organoids for the modeling of cardiac development and congenital heart disease. *Nat Commun* 2021;**12**:5142.
326. Wimmer RA, Leopoldi A, Aichinger M, Wick N, Hantusch B, Novatchkova M, Taubenschmid J, Hämmerle M, Esk C, Bagley JA, Lindenhofer D, Chen G, Boehm M, Agu CA, Yang F, Fu B, Zuber J, Knoblich JA, Kerjaschki D, Penninger JM. Human blood vessel organoids as a model of diabetic vasculopathy. *Nature* 2019;**565**:505–510.
327. Buikema JW, Wu SM. Untangling the biology of genetic cardiomyopathies with pluripotent stem cell disease models. *Curr Cardiol Rep* 2017;**19**:30.
328. van Mil A, Balk GM, Neef K, Buikema JW, Asselbergs FW, Wu SM, Doevendans PA, Sluijter JPG. Modelling inherited cardiac disease using human induced pluripotent stem cell-derived cardiomyocytes: progress, pitfalls, and potential. *Cardiovasc Res* 2018;**114**:1828–1842.
329. Martewicz S, Magnussen M, Elvassore N. Beyond family: modeling non-hereditary heart diseases with human pluripotent stem cell-derived cardiomyocytes. *Front Physiol* 2020;**11**:384.
330. Nugraha B, Buono MF, von Boehmer L, Hoerstrup SP, Emmert MY. Human cardiac organoids for disease modeling. *Clin Pharmacol Ther* 2019;**105**:79–85.
331. Hofbauer P, Jahnel SM, Papai N, Giesshammer M, Deyett A, Schmidt C, Penc M, Tavernini K, Grdseloff N, Meledeth C, Ginistrelli LC, Ctorteca C, Šalic Š, Novatchkova M, Mendjan S. Cardioids reveal self-organizing principles of human cardiogenesis. *Cell* 2021;**184**:3299–3317.e22.
332. Hoang P, Kowalczewski A, Sun S, Winston TS, Archilla AM, Lemus SM, Ercan-Sencicek AG, Gupta AR, Liu W, Kontaridis MI, Amack JD, Ma Z. Engineering spatial-organized cardiac organoids for developmental toxicity testing. *Stem Cell Rep* 2021;**16**:1228–1244.
333. Campostrini G, Meraviglia V, Giacomelli E, van Helden RWJ, Yangou L, Davis RP, Bellin M, Orlova VV, Mummery CL. Generation, functional analysis and applications of isogenic three-dimensional self-aggregating cardiac microtissues from human pluripotent stem cells. *Nat Protoc* 2021;**16**:2213–2256.

334. Lee J, Sutani A, Kaneko R, Takeuchi J, Sasano T, Kohda T, Ihara K, Takahashi K, Yamazoe M, Morio T, Furukawa T, Ishino F. *In vitro* generation of functional murine heart organoids via FGF4 and extracellular matrix. *Nat Commun* 2020;**11**:4283.
335. Drakhlis L, Biswanath S, Farr CM, Lupanow V, Teske J, Ritzenhoff K, Franke A, Manstein F, Bolesani E, Kempf H, Liebscher S, Schenke-Layland K, Hegermann J, Nolte L, Meyer H, de la Roche J, Thiemann S, Wahl-Schott C, Martin U, Zweigerdt R. Human heart-forming organoids recapitulate early heart and foregut development. *Nat Biotechnol* 2021;**39**:737–746.
336. Hoang P, Wang J, Conklin BR, Healy KE, Ma Z. Generation of spatial-patterned early-developing cardiac organoids using human pluripotent stem cells. *Nat Protoc* 2018;**13**:723–737.
337. Tadevosyan K, Iglesias-García O, Mazo MM, Prósper F, Raya A. Engineering and assessing cardiac tissue complexity. *Int J Mol Sci* 2021;**22**:1479.
338. Winbo A, Ramanan S, Eugster E, Jovine S, Skinner JR, Montgomery JM. Functional co-culture of sympathetic neurons and cardiomyocytes derived from human-induced pluripotent stem cells. *Am J Physiol Heart Circ Physiol* 2020;**319**:H927–H937.
339. Oh Y, Cho GS, Li Z, Hong I, Zhu R, Kim MJ, Kim YJ, Tampakakis E, Tung L, Hugarin R, Dong X, Kwon C, Lee G. Functional coupling with cardiac muscle promotes maturation of hPSC-derived sympathetic neurons. *Cell Stem Cell* 2016;**19**:95–106.
340. Miranda CC, Fernandes TG, Diogo MM, Cabral JMS. Towards multi-organoid systems for drug screening applications. *Bioengineering (Basel)* 2018;**5**:49.
341. Ingber DE. Developmentally inspired human 'organs on chips'. *Development* 2018;**145**:dev156125.
342. Sosa-Hernández JE, Villalba-Rodríguez AM, Romero-Castillo KD, Aguilar-Aguila-Isaías MA, García-Reyes IE, Hernández-Antonio A, Ahmed I, Sharma A, Parra-Saldivar R, Iqbal HMN. Organs-on-a-chip module: a review from the development and applications perspective. *Micromachines (Basel)* 2018;**9**:536.
343. Lincoff AM, Tardif JC, Schwartz GG, Nicholls SJ, Rydén L, Neal B, Malmberg K, Wedel H, Buse JB, Henry RR, Weichert A, Cannata R, Svensson A, Volz D, Grobbee DE. Effect of aloglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial. *JAMA* 2014;**311**:1515–1525.
344. Margulies KB, Hernandez AF, Redfield MM, Givertz MM, Oliveira GH, Cole R, Mann DL, Whellan DJ, Kiernan MS, Felker GM, McNulty SE, Anstrom KJ, Shah MR, Braunwald E, Cappola TP. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. *JAMA* 2016;**316**:500–508.
345. Weir DL, McAlister FA, Senthilvelan A, Minhas-Sandhu JK, Eurich DT. Sitagliptin use in patients with diabetes and heart failure: a population-based retrospective cohort study. *JACC Heart Fail* 2014;**2**:573–582.
346. Masoudi FA, Wang Y, Inzucchi SE, Setaro JF, Havranek EP, Foody JM, Krumholz HM. Metformin and thiazolidinedione use in Medicare patients with heart failure. *JAMA* 2003;**290**:81–85.
347. Eurich DT, Weir DL, Majumdar SR, Tsuyuki RT, Johnson JA, Tjosvold L, Vanderloo SE, McAlister FA. Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients. *Circ Heart Fail* 2013;**6**:395–402.
348. Dziubak A, Wójcicka J, Wojtak A, Bętkowski J. Metabolic effects of metformin in the failing heart. *Int J Mol Sci* 2018;**19**:2869.
349. Mao H, Li L, Fan Q, Angelini A, Saha PK, Wu H, Ballantyne CM, Hartig SM, Xie L, Pi X. Loss of bone morphogenetic protein-binding endothelial regulator causes insulin resistance. *Nat Commun* 2021;**12**:1927.
350. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, Brunner-La Rocca HP, Choi DJ, Chopra V, Chuquiere-Valenzuela E, Giannetti N, Gomez-Mesa JE, Janssens S, Januzzi JL, Gonzalez-Juanatey JR, Merkely B, Nicholls SJ, Perrone SV, Piña IL, Ponikowski P, Senni M, Sim D, Spinar J, Squire I, Taddei S, Tsutsui H, Verma S, Vinereanu D, Zhang J, Carson P, Lam CSP, Marx N, Zeller C, Sattar N, Jamal W, Schnaidt S, Schnee JM, Brueckmann M, Pocock SJ, Zannad F, Packer M. Empagliflozin in heart failure with a preserved ejection fraction. *N Engl J Med* 2021;**385**:1451–1461.
351. Castellana M, Cignarelli A, Brescia F, Perrini S, Natalicchio A, Laviola L, Giorgino F. Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: a meta-analysis. *Sci Rep* 2019;**9**:19351.
352. McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Bělohávek J, Böhm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukát A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungerman CEA, Merkely B, Nicolau JC, O'Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjöstrand M, Langkilde AM. Dapagliflozin in patients with heart failure and reduced ejection fraction. *N Engl J Med* 2019;**381**:1995–2008.
353. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. *N Engl J Med* 2015;**373**:2117–2128.
354. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR. Canagliflozin and cardiovascular and renal events in type 2 diabetes. *N Engl J Med* 2017;**377**:644–657.
355. Inzucchi SE, Kosiborod M, Fitchett D, Wanner C, Hehnke U, Kaspers S, George JT, Zinman B. Improvement in cardiovascular outcomes with empagliflozin is independent of glycemic control. *Circulation* 2018;**138**:1904–1907.
356. Cowie MR, Fisher M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. *Nat Rev Cardiol* 2020;**17**:761–772.
357. Chen J, Williams S, Ho S, Loraine H, Hagan D, Whaley JM, Feder JN. Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members. *Diabetes Ther* 2010;**1**:57–92.
358. Van Steenberghe A, Baeteu M, Ginion A, Féré L, Battault S, Ravenstein CM, Balligand JL, Daskalopoulos EP, Gilon P, Despa F, Despa S, Vanoverschelde JL, Horman S, Koepsell H, Berry G, Hue L, Bertrand L, Beauloye C. Sodium-myoinositol cotransporter-1, SMIT1, mediates the production of reactive oxygen species induced by hyperglycemia in the heart. *Sci Rep* 2017;**7**:41166.
359. Pabel S, Hamdani N, Luedde M, Sossalla S. SGLT2 inhibitors and their mode of action in heart failure-has the mystery been unravelled? *Curr Heart Fail Rep* 2021;**18**:315–328.
360. Di Franco A, Cantini G, Tani A, Coppini R, Zecchi-Orlandini S, Raimondi L, Luconi M, Mannucci E. Sodium-dependent glucose transporters (SGLT) in human ischemic heart: a new potential pharmacological target. *Int J Cardiol* 2017;**243**:86–90.
361. Li CY, Wang LX, Dong SS, Hong Y, Zhou XH, Zheng WW, Zheng C. Phlorizin exerts direct protective effects on Palmitic Acid (PA)-induced endothelial dysfunction by activating the PI3K/AKT/eNOS signaling pathway and increasing the levels of Nitric Oxide (NO). *Med Sci Monit Basic Res* 2018;**24**:1–9.
362. El-Daly M, Pulakazhi Venu VK, Saifeddine M, Mihara K, Kang S, Fedak PWM, Alston LA, Hirota SA, Ding H, Triggler CR, Hollenberg MD. Hyperglycaemic impairment of PAR2-mediated vasodilation: prevention by inhibition of aortic endothelial sodium-glucose-co-transporter-2 and minimizing oxidative stress. *Vascul Pharmacol* 2018;**109**:56–71.
363. Sukhanov S, Higashi Y, Yoshida T, Mummidi S, Aroor AR, Jeffrey Russell J, Bender SB, DeMarco VG, Chandrasekar B. The SGLT2 inhibitor empagliflozin attenuates interleukin-17A-induced human aortic smooth muscle cell proliferation and migration by targeting TRAF3IP2/ROS/NLRP3/Caspase-1-dependent IL-1 β and IL-18 secretion. *Cell Signal* 2021;**77**:109825.
364. Takahashi H, Nomiya T, Terawaki Y, Horikawa T, Kawanami T, Hamaguchi Y, Tanaka T, Motonaga R, Fukuda T, Tanabe M, Yanase T. Combined treatment with DPP-4 inhibitor linagliptin and SGLT2 inhibitor empagliflozin attenuates neointima formation after vascular injury in diabetic mice. *Biochem Biophys Res Commun* 2019;**518**:100640.
365. Díaz-Rodríguez E, Agra RM, Fernández Á L, Adrio B, García-Caballero T, González-Juanatey JR, Eiras S. Effects of dapagliflozin on human epicardial adipose tissue: modulation of insulin resistance, inflammatory chemokine production, and differentiation ability. *Cardiovasc Res* 2018;**114**:336–346.
366. Gager GM, von Lewinski D, Sourij H, Jilma B, Eyleten C, Filipiak K, Hülsmann M, Kubica J, Postula M, Siller-Matula JM. Effects of SGLT2 inhibitors on ion homeostasis and oxidative stress associated mechanisms in heart failure. *Biomed Pharmacother* 2021;**143**:112169.
367. Sugiyama S, Jinnouchi H, Kurinami N, Hieshima K, Yoshida A, Jinnouchi K, Nishimura H, Suzuki T, Miyamoto F, Kajiwara K, Jinnouchi T. The SGLT2 inhibitor dapagliflozin significantly improves the peripheral microvascular endothelial function in patients with uncontrolled type 2 diabetes mellitus. *Intern Med* 2018;**57**:2147–2156.
368. Correale M, Mazzeo P, Mallardi A, Leopizzi A, Tricarico L, Fortunato M, Magnesa M, Tucci S, Maiellaro P, Pastore G, Lamaccchia O, Iacoviello M, Di Biase M, Brunetti ND. Switch to SGLT2 inhibitors and improved endothelial function in diabetic patients with chronic heart failure. *Cardiovasc Drugs Ther* 2021. doi:10.1007/s10557-021-07254-3. Published online ahead of print.
369. Salim HM, Fukuda D, Yagi S, Soeki T, Shimabukuro M, Sata M. Glycemic control with ipragliflozin, a novel selective SGLT2 inhibitor, ameliorated endothelial dysfunction in streptozotocin-induced diabetic mouse. *Front Cardiovasc Med* 2016;**3**:43.
370. Angé M, De Poortere J, Ginion A, Battault S, Dechamps M, Muccioli GG, Roumain M, Morelle J, Druart S, Mathivet T, Bertrand L, Castaneres-Zapatero D, Horman S, Beauloye C. Canagliflozin protects against sepsis capillary leak syndrome by activating endothelial α 1AMPK. *Sci Rep* 2021;**11**:13700.
371. Giordo R, Ahmed YMA, Allam H, Abusnana S, Pappalardo L, Nasrallah GK, Mangoni AA, Pintus G. EndMT regulation by small RNAs in diabetes-associated fibrotic conditions: potential link with oxidative stress. *Front Cell Dev Biol* 2021;**9**:683594.
372. Tian J, Zhang M, Suo M, Liu D, Wang X, Liu M, Pan J, Jin T, An F. Dapagliflozin alleviates cardiac fibrosis through suppressing EndMT and fibroblast activation via AMPK α /TGF- β /Smad signalling in type 2 diabetic rats. *J Cell Mol Med* 2021;**25**:7642–7659.
373. Lee TM, Chang NC, Lin SZ. Dapagliflozin, a selective SGLT2 inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts. *Free Radic Biol Med* 2017;**104**:298–310.
374. Iannantuoni F, MdM A, Diaz-Morales N, Falcon R, Bañuls C, Abad-Jimenez Z, Victor VM, Hernandez-Mijares A, Rovira-Llopis S. The SGLT2 inhibitor empagliflozin ameliorates the inflammatory profile in type 2 diabetic patients and promotes an antioxidant response in leukocytes. *J Clin Med* 2019;**8**:1814.
375. Curtain JP, Docherty KF, Jhund PS, Petrie MC, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Bengtsson O, Langkilde AM, Sjöstrand M, Solomon SD, McMurray JJV. Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. *Eur Heart J* 2021;**42**:3727–3738.
376. Li HL, Lip GYH, Feng Q, Fei Y, Tse YK, Wu MZ, Ren QW, Tse HF, Cheung BY, Yiu KH. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis. *Cardiovasc Diabetol* 2021;**20**:100.

377. Ryan KL, Rickards CA, Hinojosa-Laborde C, Cooke WH, Convertino VA. Sympathetic responses to central hypovolemia: new insights from microneurographic recordings. *Front Physiol* 2012;**3**:110.
378. Jordan J, Tank J, Heusser K, Heise T, Wanner C, Heer M, Macha S, Mattheus M, Lund SS, Woerle HJ, Broedl UC. The effect of empagliflozin on muscle sympathetic nerve activity in patients with type II diabetes mellitus. *J Am Soc Hypertens* 2017;**11**: 604–612.
379. Scheen AJ. Effect of SGLT2 inhibitors on the sympathetic nervous system and blood pressure. *Curr Cardiol Rep* 2019;**21**:70.
380. Vvan N, Rahman A, Hitomi H, Nishiyama A. The effects of sodium-glucose cotransporter 2 inhibitors on sympathetic nervous activity. *Front Endocrinol (Lausanne)* 2018;**9**:421.
381. Matthews VB, Elliot RH, Rudnicka C, Hricova J, Herat L, Schlaich MP. Role of the sympathetic nervous system in regulation of the sodium glucose cotransporter 2. *J Hypertens* 2017;**35**:2059–2068.